CAREFUSION 10-Q 6 May 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2014	Apr. 18, 2014
Document Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CFN	'
Entity Registrant Name	'CAREFUSION Corp	'
Entity Central Index Key	'0001457543	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	207,312,079

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Income (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$968	$901	$2,720	$2,647
Cost of Products Sold	496	425	1,359	1,264
Gross Profit	472	476	1,361	1,383
Selling, General and Administrative Expenses	258	244	763	737
Research and Development Expenses	47	47	142	142
Restructuring and Acquisition Integration Charges	9	9	30	14
Reserve for Expected Government Settlement	0	41	0	41
Share of Net (Earnings) Loss of Equity Method Investee	-1	0	-1	0
Operating Income	159	135	427	449
Interest Expense and Other, Net	27	17	68	55
Income Before Income Tax	132	118	359	394
Provision for Income Tax	30	34	82	115
Income from Continuing Operations	102	84	277	279
Loss from Discontinued Operations, Net of Tax	0	0	0	-3
Net Income	$102	$84	$277	$276
Basic Earnings (Loss) per Common Share:	'	'	'	'
Continuing Operations (usd per share)	$0.49	$0.38	$1.31	$1.25
Discontinued Operations (usd per share)	$0	$0	$0	($0.01)
Basic Earnings per Common Share (usd per share)	$0.49	$0.38	$1.31	$1.24
Diluted Earnings (Loss) per Common Share:	'	'	'	'
Continuing Operations (usd per share)	$0.48	$0.37	$1.29	$1.24
Discontinued Operations (usd per share)	$0	$0	$0	($0.01)
Diluted Earnings per Common Share (usd per share)	$0.48	$0.37	$1.29	$1.23
Weighted-Average Number of Common Shares Outstanding:	'	'	'	'
Basic (shares)	208	222.5	210.8	222.4
Diluted (shares)	211.1	225.6	214	225

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net Income	$102	$84	$277	$276
Other Comprehensive Income (Loss), Net of Tax:	'	'	'	'
Foreign Currency Translation Adjustments	5	-13	24	12
Unrealized (Loss) Gain on Derivatives	-16	11	-5	16
Other Comprehensive Income, Net of Tax	-11	-2	19	28
Comprehensive Income, Net of Tax	$91	$82	$296	$304

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Millions, unless otherwise specified
Current Assets:	'	'
Cash and Cash Equivalents	$1,269	$1,798
Trade Receivables, Net	454	429
Current Portion of Net Investment in Sales-Type Leases	300	351
Inventories, Net	460	384
Prepaid Expenses	33	30
Other Current Assets	223	141
Total Current Assets	2,739	3,133
Property and Equipment, Net	442	409
Net Investment in Sales-Type Leases, Less Current Portion	981	1,001
Goodwill	3,307	3,081
Intangible Assets, Net	1,043	793
Investments in Unconsolidated Entities	95	0
Other Assets	56	136
Total Assets	8,663	8,553
Current Liabilities:	'	'
Current Portion of Long-Term Obligations and Other Short-Term Borrowings	457	2
Accounts Payable	199	147
Deferred Revenue	69	51
Accrued Compensation and Benefits	146	150
Other Accrued Liabilities	203	242
Total Current Liabilities	1,074	592
Long-Term Obligations, Less Current Portion	999	1,444
Deferred Income Taxes	728	638
Other Liabilities	461	493
Total Liabilities	3,262	3,167
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Preferred Stock (50.0 Authorized Shares; $.01 Par Value) Issued – None	0	0
Common Stock (1,200.0 Authorized Shares; $.01 Par Value) Issued – 233.7 and 229.4 shares at March 31, 2014 and June 30, 2013, respectively	2	2
Treasury Stock, at cost, 26.1 and 15.5 shares at March 31, 2014 and June 30, 2013, respectively	-915	-505
Additional Paid-In Capital	5,015	4,886
Retained Earnings	1,325	1,048
Accumulated Other Comprehensive Loss	-26	-45
Total Stockholders' Equity	5,401	5,386
Total Liabilities and Stockholders' Equity	$8,663	$8,553

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
Statement of Financial Position [Abstract]	'	'
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Par Value (usd per share)	$0.01	$0.01
Preferred Stock, Shares Issued	0	0
Common Stock, Shares Authorized	1,200,000,000	1,200,000,000
Common Stock, Par Value (usd per share)	$0.01	$0.01
Common Stock, Shares Issued	233,700,000	229,000,000
Treasury Stock, Shares	26,100,000	15,500,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement of Cash Flows [Abstract]	'	'
Cash and Cash Equivalents at July 1, Attributable to Continuing Operations	$1,798	$1,648
Cash and Cash Equivalents at July 1, Attributable to Discontinued Operations	0	-1
Cash Flows from Operating Activities:	'	'
Net Income	277	276
Loss from Discontinued Operations	0	-3
Income from Continuing Operations	277	279
Adjustments to Reconcile Income from Continuing Operations to Net Cash Provided by Operating Activities:	'	'
Depreciation and Amortization	146	137
Other Non-Cash Items	47	63
Change in Operating Assets and Liabilities, Excluding Impact of Acquired Assets and Assumed Liabilities:	'	'
Trade Receivables	4	6
Inventories	-32	-6
Net Investment in Sales-Type Leases	70	8
Accounts Payable	38	4
Other Accrued Liabilities and Operating Items, Net	-95	-66
Net Cash Provided by Operating Activities - Continuing Operations	455	425
Net Cash Provided by Operating Activities - Discontinued Operations	0	1
Net Cash Provided by Operating Activities	455	426
Cash Flows from Investing Activities:	'	'
Cash Paid for Acquisitions, Net of Cash Received	-517	-66
Cash Paid for Investments in Unconsolidated Entities	-94	0
Additions to Property and Equipment	-61	-63
Other Investing Activities	-2	-14
Net Cash Used in Investing Activities – Continuing Operations	-674	-143
Net Cash Used in Investing Activities	-674	-143
Cash Flows from Financing Activities:	'	'
Repayment of Long-Term Obligations	-2	-251
Share Repurchase Programs	-407	-108
Proceeds from Issuance of Debt, Net	-1	298
Proceeds from Stock Option Exercises	93	43
Other Financing Activities	-7	-13
Net Cash Used in Financing Activities – Continuing Operations	-324	-31
Net Cash Used in Financing Activities	-324	-31
Effect of Exchange Rate Changes on Cash	14	6
Net (Decrease) Increase in Cash and Cash Equivalents – Continuing Operations	-529	257
Net Increase in Cash and Cash Equivalents - Discontinued Operations	0	1
Net (Decrease) Increase in Cash and Cash Equivalents	-529	258
Cash and Cash Equivalents at March 31, Attributable to Continuing Operations	1,269	1,905
Cash and Cash Equivalents at March 31, Attributable to Discontinued Operations	0	0
Non-cash Investing and Financing Activities:	'	'
Asset Acquired by Entering into Capital Lease	4	0
Share Repurchase Programs	$3	$4

Basis_Of_Presentation

Basis Of Presentation	9 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis Of Presentation	'
	BASIS OF PRESENTATION
	Basis of Presentation. Unless the context otherwise requires, references in these notes to the unaudited condensed consolidated financial statements to “CareFusion Corporation”, “CareFusion”, “we”, “us”, “our”, “the company” and “our company” refer to CareFusion Corporation and its consolidated subsidiaries. References in these notes to the unaudited condensed consolidated financial statements to “Cardinal Health” refer to Cardinal Health, Inc., an Ohio corporation, and its consolidated subsidiaries.
	We were incorporated in Delaware on January 14, 2009 for the purpose of holding the clinical and medical products businesses of Cardinal Health in anticipation of spinning off from Cardinal Health. We completed the spinoff from Cardinal Health on August 31, 2009.
	The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at June 30, 2013 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended June 30, 2013, filed with the SEC with our Annual Report on Form 10-K on August 9, 2013 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
	We have evaluated subsequent events for recognition or disclosure through the date these financial statements were issued.
	Our two global operating and reportable segments are Medical Systems and Procedural Solutions, which focus primarily on our medical equipment business lines and disposable products business lines, respectively:
	Medical Systems. The Medical Systems segment is organized around our medical equipment business lines. Within the Medical Systems segment, we operate our Dispensing Technologies, Infusion Systems and Respiratory Technologies business lines. The Dispensing Technologies business line includes equipment and related services for medication and supply dispensing. The Infusion Systems business line includes infusion pumps and dedicated disposable infusion sets and accessories. The Respiratory Technologies business line includes respiratory ventilators and dedicated disposable ventilator circuits and accessories, as well as our respiratory diagnostics products. We also include our data mining surveillance service business within the Medical Systems segment, which we report as “Other.”
	Procedural Solutions. The Procedural Solutions segment is organized around our disposable products and reusable surgical instruments business lines. Within the Procedural Solutions segment, we operate our Infection Prevention, Medical Specialties and Specialty Disposables business lines. The Infection Prevention business line includes single-use skin antiseptic and other patient-preparation products and non-dedicated disposable infusion administration sets and accessories. The Medical Specialties business line includes interventional specialty products used for biopsy, drainage and other procedures, as well as reusable surgical instruments. The Specialty Disposables business line includes non-dedicated disposable ventilator circuits, single-use consumables for respiratory care and anesthesiology, and oxygen masks used in respiratory therapy.
	New Accounting Pronouncements (Adopted during Fiscal Year 2014)
	ASU 2011-11 & ASU 2013-01. In December 2011 the Financial Accounting Standards Board (“FASB”) issued ASU 2011-11 – Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”), and in January 2013 issued ASU 2013-01 – Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (“ASU 2013-01”). ASU 2011-11 addresses disclosure differences between GAAP and International Financial Reporting Standards regarding balance sheet offsetting of certain derivative and repurchase agreement arrangements. ASU 2013-01 clarifies the scope of the provisions of ASU 2011-11. We adopted the requirements of ASU 2011-11 and ASU 2013-01 during the quarter ended September 30, 2013. The adoptions of ASU 2011-11 and ASU 2013-01 had no material impact on our financial condition, results of operations or cash flows.
	ASU 2013-02. In February 2013, the FASB issued ASU 2013-02 – Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). ASU 2013-02 requires public entities to include information about both (i) changes in Accumulated Other Comprehensive Income (“AOCI”) by component, and (ii) significant items reclassified out of AOCI. We adopted the requirements of ASU 2013-02 during the quarter ended September 30, 2013. The adoption of ASU 2013-02 had no material impact on our financial condition, results of operations or cash flows.

Acquisitions_Notes

Acquisitions (Notes)	9 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	ACQUISITIONS
	Acquisition of Vital Signs
	On November 18, 2013, we announced the signing of a definitive agreement to acquire the Vital Signs business of General Electric Company’s Healthcare division (“Vital Signs”) for $500 million. Vital Signs is a leading manufacturer of single-use consumables for respiratory care and anesthesiology, and also markets products for temperature management and patient monitoring consumables. On December 30, 2013, in connection with the first closing of this transaction, we acquired the outstanding equity of certain entities included within the Vital Signs business and other business assets and liabilities in the U.S., China and certain other geographies using approximately $473 million of cash on hand. In March 2014, we completed the second closing of this transaction related to various countries using approximately $17 million of cash on hand. The balance of the purchase price will be paid upon completion of the acquisition of the assets of the remaining international operations of Vital Signs, pending successful regulatory review and customary closing conditions. The purchase prices associated with the first two closings and future closings are subject to adjustments for net working capital, to be determined within 90 days following the applicable closing date. The results of the first two closings of this transaction are included in the Procedural Solutions segment commencing from the applicable acquisition date.
	The transaction has been accounted for as a business combination and requires, among other things, that assets acquired and liabilities assumed are recognized at their fair values as of the acquisition date.
	Based on our preliminary estimates of the net working capital adjustment, and net of cash and cash equivalents acquired, we determined a net purchase price associated with the first and second closings, as set forth below. The following table summarizes the preliminary allocation of the net purchase price to the fair values of the tangible and identifiable intangible assets acquired and liabilities assumed in connection with the first and second closings, based on their estimated fair values at the applicable acquisition date. Certain estimated values, including goodwill, intangible assets and deferred income taxes, are not yet finalized pending the final settlement of the purchase price and purchase price allocations and are subject to change once additional information is obtained. Balances are reflected in the accompanying condensed consolidated balance sheets as of March 31, 2014.
	(in millions)	First			Second
		Closing			Closing
	Cash Paid	$	473		$	17
	Cash and Cash Equivalents Acquired, Less Estimated Net Working Capital Adjustments	(13		)	—
	Net Purchase Price	$	460		$	17
	(in millions)	First			Second
		Closing			Closing
	Trade Receivables	$	20		$	—
	Inventories	31			8
	Other Current Assets	13			—
	Property and Equipment	35			—
	Intangible Assets	302			—
	Goodwill	207			10
	Current Liabilities and Borrowings	(41		)	(1		)
	Deferred Income Taxes	(102		)	—
	Other Long-Term Liabilities	(5		)	—
	Net Assets Acquired	$	460		$	17
	Intangible assets represent customer relationships ($261 million), developed technology ($31 million), and trademarks and patents ($10 million) which have estimated weighted average useful lives of 20 years, 7 years and 6 years, respectively. The intangible assets have a total estimated weighted average useful life of 18 years. The preliminary estimated fair value of the identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, research and development expenses, selling and marketing costs and working capital/asset contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, competitive trends impacting the asset and each cash flow stream as well as other factors. The discount rates used to arrive at the present value of intangible assets as of the acquisition date ranged from 10.5% to 12.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.
	Various factors contributed to the establishment of goodwill, including an expanded global footprint and scale, Vital Signs’ history of operating margins and profitability, and the opportunity for us to generate revenue by supplementing our existing respiratory and anesthesia consumables product portfolios. The goodwill recognized from the Vital Signs acquisition may be deductible for tax purposes to the extent related to the acquisition of identifiable intangible assets. All goodwill from the Vital Signs acquisition was assigned to the Procedural Solutions segment.
	Deferred income taxes result from fair value adjustments to identifiable intangible assets. In a stock acquisition associated with the purchase of a business, the fair value adjustments create excess book basis over the tax basis of those assets for which we record deferred income tax liabilities using the statutory tax rate for the jurisdiction in which the deferred income taxes exist.
	In connection with the Vital Signs transaction, we recorded acquisition costs of approximately $4 million in Selling, General and Administrative expenses for the nine months ended March 31, 2014, for advisory, legal, regulatory and other related costs. During the quarter ended March 31, 2014, acquisition costs related to the Vital Signs transaction were not material.
	Pro forma results of operations have not been presented because the effect of the acquisition was not material to our unaudited condensed consolidated financial statements.
	Acquisition of Grupo Sendal
	On October 1, 2013, we completed the acquisition of Grupo Sendal, S.L (“Sendal”), an infusion specialty disposable manufacturer in Spain that primarily serves the western European market. We funded the acquisition with existing cash and funds generated from operations. The acquisition of Sendal was not material to our unaudited condensed consolidated financial statements.

Investments_in_Unconsolidated_

Investments in Unconsolidated Entities Investments in Unconsolidated Entities (Notes)	9 Months Ended
	Mar. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
Investments in Unconsolidated Entities	'
	INVESTMENTS IN UNCONSOLIDATED ENTITIES
	Investments in unconsolidated entities in privately held companies include equity investments accounted for under the equity method based on the ability to exert significant influence and equity investments accounted for under the cost method based on the lack of significant influence and readily determinable fair value. The following table sets forth information relating to these investments:
	(in millions)	March 31,		June 30,
		2014		2013
	Equity Method Investments
	Cost	$	90	$	—
	Share of Net Earnings of Equity Method Investee	1		—
	Carrying Value of Equity Method Investments	$	91	$	—
	Cost Method Investments
	Carrying Value of Cost Method Investments	$	4	$	—
	Total Investments in Unconsolidated Entities	$	95	$	—
	The investments accounted for under the equity method consist of a 40 percent non-controlling equity interest in Caesarea Medical Electronics Ltd. (“CME”), a global infusion pump manufacturer. CME, headquartered in Israel, designs, manufactures and markets a range of infusion and syringe pumps as well as related accessories and disposable administration sets for both homecare and hospital settings. We completed this investment transaction in March 2014 and received a 40 percent non-controlling equity interest in CME for approximately $89 million, which we funded with existing cash on hand. CME continues to operate independently from us. Additionally, we have the right to increase our ownership percentage by purchasing an additional 40 percent equity interest of CME ("Call Option"), exercisable any time before March 2017. The seller also has the right to require CareFusion to acquire the remaining 60 percent of CME ("Put Option"), which is exercisable only upon certain conditions, one of which is if we fail to exercise our Call Option. The Call Option and Put Option were deemed to be freestanding financial instruments. The Call Option does not meet the definition of a derivative and the Put Option's fair value is not material to warrant separate accounting. The Company determined that CME did not meet the definition of a Variable Interest Entity ("VIE").

Earnings_Per_Share_Notes

Earnings Per Share (Notes)	9 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	EARNINGS PER SHARE
	For the quarters and nine months ended March 31, 2014 and 2013, basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is calculated to give effect to all dilutive securities, using the treasury stock method.
	The following table sets forth the reconciliation of basic and diluted earnings per share for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended		Nine Months Ended
		March 31,		March 31,
	(shares in millions)	2014	2013	2014	2013
	Denominator for Basic Earnings per Share	208	222.5	210.8	222.4
	Effect of Dilutive Securities:
	Stock Options	2	1.9	2.1	1.4
	Restricted Stock Units and Performance Stock Units	1.1	1.2	1.1	1.2
	Denominator for Diluted Earnings per Share - Adjusted for Dilutive Securities	211.1	225.6	214	225
	The potentially dilutive stock options, restricted stock units and performance stock units that would have been excluded because the effect would have been antidilutive was 1.7 million and 1.7 million for the quarter and nine months ended March 31, 2014, respectively, as compared to 4.0 million and 6.5 million for the quarter and nine months ended March 31, 2013, respectively.
	Basic and diluted earnings per share amounts are computed independently in the unaudited condensed consolidated statements of income. Therefore, the sum of per share components may not equal the per share amounts presented.
	In February 2012, we announced that our Board of Directors had approved a share repurchase program authorizing the repurchase of up to $500 million of our common stock through open market and private transactions. The cost of repurchased shares is included in treasury stock and reported as a reduction in total equity when a repurchase occurs. This share repurchase program was completed in June 2013. Under this program, we repurchased a total of 15.3 million shares of our common stock for an aggregate of $500 million (excluding commissions and fees). In August 2013, we announced that our Board of Directors had approved a new share repurchase program authorizing the repurchase of up to $750 million of our common stock. Under this program, we are authorized to repurchase our shares in open market and private transactions through December 2015. During the quarter ended March 31, 2014, we purchased a total of 2.5 million shares under this program for an aggregate of $103 million (excluding commissions and fees). During the nine months ended March 31, 2014, we purchased a total of 10.6 million shares under this program for an aggregate of $410 million (excluding commissions and fees). From April 1, 2014 through the date of this filing, we purchased an additional 0.9 million shares under this program for an aggregate of $35 million (excluding commissions and fees). We expect to continue to manage the pace of repurchases under this program based on market conditions and other relevant factors, and we currently intend to complete approximately $500 million of repurchases authorized by this program in fiscal 2014.

Restructuring_And_Acquisition_

Restructuring And Acquisition Integration Charges	9 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring And Acquisition Integration Charges	'
	RESTRUCTURING AND ACQUISITION INTEGRATION CHARGES
	Restructuring and acquisition integration charges are expensed as incurred.
	The following is a summary of restructuring and acquisition integration charges for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended				Nine Months Ended
		March 31,				March 31,
	(in millions)	2014		2013		2014			2013
	Restructuring Charges	$	7	$	9	$	28		$	14
	Acquisition Integration Charges	2		—		2			—
	Total Restructuring and Acquisition Integration Charges	$	9	$	9	$	30		$	14
	Restructuring Charges
	We periodically incur costs to implement restructuring efforts for specific operations, which are recorded within our unaudited condensed consolidated statements of income as they are incurred. The restructuring plans focus on various aspects of operations, including closing and consolidating certain manufacturing operations, rationalizing headcount, and aligning operations in the most strategic and cost-efficient structure.
	The following tables include information regarding our current restructuring programs:
		Nine Months Ended March 31, 2014
	(in millions)	Accrued at		Accrued Costs		Cash Payments			Accrued at March 31, 20141
		June 30, 20131
	Total Restructuring Programs	$	7	$	28	$	(22	)	$	13
	________________
	1 Included within “Other Accrued Liabilities” in the unaudited condensed consolidated balance sheets.
		Nine Months Ended March 31, 2013
	(in millions)	Accrued at		Accrued Costs2		Cash Payments			Accrued at March 31, 20131
		June 30, 20121
	Total Restructuring Programs	$	10	$	14	$	(15	)	$	9
	________________
	1 Included within “Other Accrued Liabilities” in the unaudited condensed consolidated balance sheets.
	2 Cash payments associated with accrued restructuring costs are expected to occur through the end of fiscal year 2015.
	The following table segregates our restructuring charges into our reportable segments for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended				Nine Months Ended
		March 31,				March 31,
	(in millions)	2014		2013		2014			2013
	Medical Systems	$	3	$	7	$	16		$	10
	Procedural Solutions	4		2		12			4
	Total Restructuring Charges	$	7	$	9	$	28		$	14
	Acquisition Integration Charges
	Costs of integrating operations of various acquired companies are recorded as acquisition integration charges when incurred.
	Certain restructuring and acquisition costs are based upon estimates. Actual amounts paid may ultimately differ from these estimates. If additional costs are incurred or recognized amounts exceed costs, such changes in estimates are recognized when they occur.

Inventories

Inventories	9 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	Inventories, accounted for at the lower of cost or market on the FIFO method, consisted of the following:
	(in millions)	March 31,			June 30,
		2014			2013
	Raw Materials	$	169		$	141
	Work-in-Process	31			23
	Finished Goods	312			264
		512			428
	Reserve for Excess and Obsolete Inventories	(52		)	(44		)
	Inventories, Net	$	460		$	384

Financing_Receivables

Financing Receivables	9 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Financing Receivables	'
	FINANCING RECEIVABLES
	Our net investment in sales-type leases comprises our portfolio of financing receivables, which primarily arise from the leasing of our dispensing equipment. The methodology for determining our allowance for credit losses is mainly based on the collective population of this portfolio segment. Allowances for credit losses on the entire portfolio are based on historical experience loss rates and the potential impact of anticipated changes in business practices, market dynamics, and economic conditions. We also reserve individual balances based on the evaluation of customers’ specific circumstances. We write off amounts that are deemed uncollectible. Financing receivables are generally considered past due 30 days after the billing date. We do not accrue interest on past due financing receivables.
	The change in the allowance for credit losses on financing receivables for the nine months ended March 31, 2014 consisted of the following:
	(in millions)
	Balance of allowance for credit losses at June 30, 2013	$	7
	Charge-offs	—
	Recoveries	—
	Provisions	—
	Balance of allowance for credit losses at March 31, 2014	$	7
	The following table summarizes the credit losses and recorded investment in sales-type leases as of March 31, 2014:
	(in millions)
	Allowance for credit losses:
	Balance at March 31, 2014	$	7
	Balance: individually evaluated for impairment	$	2
	Balance: collectively evaluated for impairment	$	5
	Net Investment in Sales-Type Leases:
	Balance at March 31, 2014	$	1,281
	Balance: individually evaluated for impairment	$	3
	Balance: collectively evaluated for impairment	$	1,278

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets	9 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill And Other Intangible Assets	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	Goodwill
	The following table summarizes the changes in the carrying amount of goodwill:
	(in millions)	Total
	Balance at June 30, 2013	$	3,081
	Goodwill Acquired, Net of Purchase Price Adjustments	223
	Foreign Currency Translation Adjustments	3
	Balance at March 31, 2014	$	3,307
	As of March 31, 2014, goodwill for the Medical Systems segment and the Procedural Solutions segment was $2,106 million and $1,201 million, respectively. As of June 30, 2013, goodwill for the Medical Systems segment and the Procedural Solutions segment was $2,103 million and $978 million, respectively. The amount set forth above for goodwill acquired reflects the impact of business acquisitions. See note 2 for further information.
	Intangible Assets
	Intangible assets with definite lives are amortized over their useful lives which range from 1 to 20 years. The detail of intangible assets by class is as follows:
	(in millions)		Weighted		Gross Intangibles				Accumulated				Net Intangibles
			Average Life (years)						Amortization
	31-Mar-14
	Unamortized Intangibles:
	Trademarks		Indefinite		307				—				307
	Total Unamortized Intangibles				307				—				307
	Amortized Intangibles:
	Trademarks and Patents1		10		99				53				46
	Developed Technology2		10		450				233				217
	Customer Relationships1		18		745				295				450
	Other		7		61				38				23
	Total Amortized Intangibles		14		1,355				619				736
	Total Intangibles				$	1,662			$	619			$	1,043
	June 30, 2013
	Unamortized Intangibles:
	In-Process Research and Development2		Indefinite		$	45			$	—			$	45
	Trademarks		Indefinite		307				—				307
	Total Unamortized Intangibles				352				—				352
	Amortized Intangibles:
	Trademarks and Patents		11		88				47				41
	Developed Technology		9		368				200				168
	Customer Relationships		16		480				275				205
	Other		7		61				34				27
	Total Amortized Intangibles		12		997				556				441
	Total Intangibles				$	1,349			$	556			$	793
	________________
	1 During the quarter ended December 31, 2013, we acquired Vital Signs, which resulted in recognition of $261 million of customer relationships, $31 million of developed technology, and $10 million of trademarks and patents, which have estimated weighted average useful lives of 20 years, 7 years and 6 years, respectively.
	2 During the quarter ended March 31, 2014, we reclassified in-process research and development associated with the Medegen acquisition to developed technology due to commercialization. The developed technology will be amortized over 15 years.
	Amortization expense is as follows:
			Quarters Ended								Nine Months Ended
			March 31,								March 31,
	(in millions)		2014				2013				2014				2013
	Amortization Expense		$	25			$	19			$	62			$	56
	Amortization expense for each of the next five fiscal years is estimated to be:
	(in millions)		2014				2015				2016				2017		2018
	Amortization Expense		$	86			$	85			$	86			$	81	$	70

Reclassifications_Out_Of_Accum

Reclassifications Out Of Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Reclassifications Out Of Accumulated Other Comprehensive Income	'
	RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME
	The summary of activity of comprehensive income (loss) for the quarter and nine months ended March 31, 2014 is as follows:
		Before-Tax			Tax (Expense) or Benefit			Net-of-Tax Amount
	Quarter Ended March 31, 2014	Amount
	Foreign Currency Translation Adjustments:
	Translation Adjustments Arising During the Period	$	5		$	—		$	5
	Reclassification Adjustments Recognized in Net Income	—			—			—
	Net Foreign Currency Translation Adjustments	5			—			5
	Interest Rate Swaps:
	Unrealized Gain (Loss) Arising During the Period	(26		)	10			(16		)
	Reclassification Adjustment Recognized in Net Income	—			—			—
	Net Gain (Loss) on Interest Rate Swaps	(26		)	10			(16		)
	Total Other Comprehensive Income (Loss)	$	(21	)	$	10		$	(11	)
		Before-Tax			Tax (Expense) or Benefit			Net-of-Tax Amount
	Nine Months Ended March 31, 2014	Amount
	Foreign Currency Translation Adjustments:
	Translation Adjustments Arising During the Period	$	26		$	(2	)	$	24
	Reclassification Adjustments Recognized in Net Income	—			—			—
	Net Foreign Currency Translation Adjustments	26			(2		)	24
	Interest Rate Swaps:
	Unrealized Gains (Loss) Arising During the Period	(8		)	3			(5		)
	Reclassification Adjustment Recognized in Net Income	—			—			—
	Net Gain (Loss) on Interest Rate Swaps	(8		)	3			(5		)
	Total Other Comprehensive Income (Loss)	$	18		$	1		$	19
	Reclassification adjustment gains and losses are included in the unaudited condensed consolidated statements of income in “Interest Expense and Other, Net”.

Borrowings

Borrowings	9 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Borrowings	'
	BORROWINGS
	Borrowings consisted of the following:
	(in millions)	March 31,		June 30,
		2014		2013
	Senior Notes due 2014, 5.125% Less Unamortized Discount of $0.7 million at March 31, 2014 and $1.8 million at June 30, 2013, Effective Rate 5.49%	$	449	$	448
	Senior Notes due 2019, 6.375% Less Unamortized Discount of $9.9 million at March 31, 2014 and $11.0 million at June 30, 2013, Effective Rate 6.69%	690		689
	Senior Notes due 2023, 3.300% Less Unamortized Discount of $2.0 million at March 31, 2014 and $2.2 million at June 30, 2013, Effective Rate 3.39%	298		298
	Euro Denominated Debt, Interest Averaging 3.52% at March 31, 2014 and 3.53% at June 30, 2013, Due in Varying Installments through 2020	10		11
	Other Obligations; Interest Averaging 6.45% at March 31, 2014 and 12.43% at June 30, 2013, Due in Varying Installments through 2017	9		—
	Total Borrowings	1,456		1,446
	Less: Current Portion	457		2
	Long-Term Portion	$	999	$	1,444
	Senior Unsecured Notes. In July 2009, we sold $1.4 billion aggregate principal amount of senior notes and received net proceeds of $1.374 billion. In August 2012, we used $250 million in cash to repay upon maturity the $250 million aggregate principal amount of the 4.125% senior notes due 2012. In March 2013, we issued $300 million aggregate principal amount of senior notes and received net proceeds of approximately $298 million. The senior notes are unsecured obligations and the discount on sale of the senior notes is amortized to interest expense utilizing the effective interest rate method.
	Euro Denominated Debt. In connection with our acquisition of Rowa Automatisierungssysteme GmbH (“Rowa”) on August 1, 2011, we assumed a 9 million Euro debt facility comprised of four tranches with annual interest rates ranging from 2.65% to 3.75%. These loans are payable in quarterly or semi-annual installments, with the final payment due September 30, 2020. At March 31, 2014 and June 30, 2013, the aggregate outstanding balance on these loans was $10 million and $11 million, respectively.
	Revolving Credit Facility. In July 2011, we entered into a five-year senior unsecured revolving credit facility with an aggregate available principal amount of $550 million. Effective as of December 10, 2012, we increased the aggregate commitments available under the credit facility from $550 million to $750 million, pursuant to the exercise of the accordion feature under the credit facility.
	On February 3, 2014, we drew down $50 million in principal amount under our five-year senior unsecured revolving credit facility.  The proceeds of the draw down were used for general corporate purposes. We repaid this loan on February 13, 2014.
	Effective February 13, 2014, we amended and restated our five-year senior unsecured revolving credit facility. This modification, among other things (i) extends the maturity date of the credit facility from July 6, 2016 to February 13, 2019; (ii) includes lower applicable interest rates; (iii) subject to certain conditions, provides CareFusion the option to increase the commitments under the credit facility by up to $250 million, to the extent that existing or new lenders agree to provide such additional commitments; (iv) includes a $25 million letter of credit sub-facility; and (v) provides additional flexibility for borrowings in currencies other than U.S. dollars. The other material terms of the credit facility, including covenants, remain unchanged. Borrowings under the amended and restated credit facility bear interest at a rate per annum that is comprised of a reference rate, which is generally based on the British Bankers Association LIBOR Rate, Federal Funds Rate, or prime rate, plus an applicable margin, which varies based upon CareFusion’s debt ratings. The amended and restated credit facility also requires us to pay a quarterly commitment fee to the lenders under the amended and restated credit facility on the amount of the lender’s unused commitments thereunder based upon CareFusion’s debt ratings. The amended and restated credit facility contains several customary covenants including, but not limited to, limitations on liens, subsidiary indebtedness, dispositions, and transactions with affiliates. In addition, the amended and restated credit facility contains financial covenants requiring us to maintain a consolidated leverage ratio of no more than 3.50:1.00 as of the end of any period of four fiscal quarters, and a consolidated interest coverage ratio of at least 3.50:1.00 as of the end of any period of the most recent four fiscal quarters. The amended and restated credit facility is subject to customary events of default, including, but not limited to, non-payment of principal or other amounts when due, breach of covenants, inaccuracy of representations and warranties, cross-default to other material indebtedness, certain ERISA-related events, certain voluntary and involuntary bankruptcy events, and change of control. We were in compliance with all of the amended and restated credit facility covenants at March 31, 2014.
	At March 31, 2014 and June 30, 2013, there were no amounts outstanding under the amended and restated credit facility or the five-year senior unsecured revolving credit facility.
	Other Obligations. We maintain other obligations that consist primarily of additional notes, loans and capital leases, which were $9 million at March 31, 2014 (net of an unamortized discount of $1 million) and were not material at June 30, 2013. Obligations related to capital leases are secured by the underlying assets, and the discount on principal balance is amortized to interest expense utilizing the effective interest rate method. Included within this $9 million was a 24 million Chinese Yuan debt facility that we assumed in connection with our acquisition of Vital Signs. This loan has an annual interest rate of 5.60% and is payable in monthly installments, with the final payment due May 30, 2014. At March 31, 2014, the aggregate outstanding balance on this loan was $4 million.
	Letters of Credit and Bank Guarantees. At March 31, 2014 and June 30, 2013, we had $27 million and $24 million, respectively, of letters of credit and bank guarantees outstanding.

Income_Tax

Income Tax	9 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax	'
	INCOME TAXES
	The effective tax rate was 23.0% and 22.9% for the quarter and nine months ended March 31, 2014, respectively, as compared to 28.6% and 29.2% for the quarter and nine months ended March 31, 2013, respectively.
	The difference between the effective tax rate for the quarter ended March 31, 2014 and the U.S. federal statutory rate of 35% is attributable to the favorable impact of foreign earnings taxed at less than the U.S. statutory rate and a tax settlement with foreign tax authorities, offset partially by unfavorable adjustments related to the United States taxation of certain foreign earnings as Subpart F income. The settlement with the foreign tax authorities resulted in a reduction in tax liability of $10 million, which was recorded in the consolidated statements of income in "Provision for Income Tax". In connection with this settlement, the Company also recorded a loss of $10 million related to the write down of an indemnification receivable related to the tax liability, which is reflected in the consolidated statements of income in "Interest Expense and Other, Net," Accordingly, the impact of this settlement on net income was zero.
	During the quarter ended September 30, 2008, Cardinal Health received an IRS Revenue Agent’s Report for the fiscal years 2003 through 2005 that included Notices of Proposed Adjustment for additional taxes related to transfer pricing arrangements between foreign and domestic subsidiaries and the transfer of intellectual property among our subsidiaries. The amount of additional tax proposed by the IRS in these notices totaled $462 million, excluding penalties and interest. During the quarter ended June 30, 2013, we and Cardinal Health entered into a closing agreement with the IRS to effectively settle $450 million of the $462 million of additional tax proposed by the IRS related to the transfer of intellectual property among our subsidiaries. In connection with the settlement, we agreed to pay $80 million ($69 million net of tax) including $26 million of interest. During the quarter ended September 30, 2013, we and Cardinal Health entered into a second closing agreement with the IRS to resolve the remaining tax uncertainties. As part of the second closing agreement, we agreed to pay $12 million ($11 million net of tax) including $5 million of interest, which is reflected in our financial results for the quarter ended September 30, 2013.
	During the quarter ended December 31, 2010, we received an IRS Revenue Agent’s Report for fiscal years 2006 and 2007 that included Notices of Proposed Adjustment for additional taxes related to transfer pricing arrangements between foreign and domestic subsidiaries. Additionally, during the quarter ended March 31, 2014, we received Notices of Proposed Adjustment for fiscal years 2008 and 2009 for additional taxes related to certain foreign earnings. We and Cardinal Health disagree with the IRS regarding its application of the United States Treasury regulations to the arrangements under review and the valuations underlying such adjustments and intend to vigorously contest them. The tax matters agreement that we entered into with Cardinal Health in connection with the spinoff generally provides that the control of audit proceedings and payment of any additional liability related to our business is our responsibility. We are currently before the IRS Appeals office for fiscal years 2006 and 2007, and continue to engage in substantive discussions related to these fiscal years. Upon completion of the IRS audit for fiscal years 2008 and 2009, we expect to appeal the Notices of Proposed Adjustment related to the taxation of certain foreign earnings.
	We are currently subject to IRS audits for fiscal years 2008 through 2012. The IRS audits for fiscal years 2008 and 2009, and the short period July 1, 2009 through August 31, 2009, are part of Cardinal Health’s tax audit of its federal consolidated returns covering periods prior to our spinoff from Cardinal Health. The IRS audits for the short period September 1, 2009 through June 30, 2010, and fiscal years 2011 and 2012, relate to federal consolidated returns filed by us following our spinoff from Cardinal Health.
	We believe that we have provided adequate tax reserves for these matters. However, if upon the conclusion of these audits, the ultimate determination of taxes owed is for an amount that is materially different than our current reserves, our overall tax expense and effective tax rate may be materially impacted in the period of adjustment.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments And Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, other pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual or disclosure in our consolidated financial statements. An estimated loss contingency is accrued in our consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, we may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against us may be unsupported, exaggerated or unrelated to reasonably possible outcomes, and as such are not meaningful indicators of our potential liability. We regularly review contingencies to determine the adequacy of our accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows, financial position, or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding could reasonably have a material effect on our business and financial condition will depend on a number of variables, including: the timing and amount of such losses; the structure, type and significance of any remedies; and the unique facts and circumstances of the particular matter that may give rise to additional factors.
	Administrative Subpoenas. In April 2011, we received a federal administrative subpoena from the U.S. Department of Justice (“Department of Justice”) through the U.S. Attorney for the District of Kansas. In addition, in September 2011, we received a federal administrative subpoena from the Office of Inspector General (“OIG”) of the Department of Health and Human Services. In August 2012, we received another federal subpoena from the Department of Justice containing additional information requests. All three subpoenas requested documents and other materials that related primarily to our sales and marketing practices for our ChloraPrep skin preparation product and information regarding our relationships with healthcare professionals. In April 2013, we announced that we had reached an agreement in principle to pay the government approximately $41 million to resolve the government’s allegations. In connection with these matters, we also entered into a non-prosecution agreement and agreed to continue to cooperate with the government. During the year ended June 30, 2013, we recorded a charge to establish a reserve for the amount of the expected payment. In January 2014, we entered into a final settlement agreement with the government, and we paid the settlement.
	FDA Consent Decree. We are operating under an amended consent decree with the FDA related to our infusion pump business in the United States. We entered into a consent decree with the FDA in February 2007 related to our Alaris SE pumps, and in February 2009, we and the FDA amended the consent decree to include all infusion pumps manufactured by or for CareFusion 303, Inc., our subsidiary that manufactures and sells infusion pumps in the United States. The amended consent decree does not apply to intravenous administration sets and accessories.While we remain subject to the amended consent decree, which includes the requirements of the consent decree, we have made substantial progress in our compliance efforts. In accordance with the consent decree, we reconditioned Alaris SE pumps that had been seized by the FDA, remediated Alaris SE pumps in use by customers, and had an independent expert inspect the Alaris SE pump facilities and provide a certification to the FDA as to compliance. As a result of these efforts, in January 2010, we announced that the FDA had given us permission to resume the manufacturing and marketing of our Alaris SE pumps. In accordance with the amended consent decree, and in addition to the requirements of the original consent decree, we also implemented a corrective action plan to bring the Alaris System and all other infusion pumps in use in the United States market into compliance, had our infusion pump facilities inspected by an independent expert, and had our recall procedures and all ongoing recalls involving our infusion pumps inspected by an independent recall expert. In July 2010, the FDA notified us that we can proceed to the audit inspection phase of the amended consent decree, which includes the requirement to retain an independent expert to conduct periodic audits of our infusion pump facilities. The amended consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing, recall products and take other actions. We may be required to pay damages of $15,000 per day per violation if we fail to comply with any provision of the amended consent decree, up to $15 million per year.
	We cannot currently predict the outcome of this matter, whether additional amounts will be incurred to resolve this matter, if any, or the matter’s ultimate impact on our business. We may be obligated to pay more costs in the future because, among other things, the FDA may determine that we are not fully compliant with the amended consent decree and therefore impose penalties under the amended consent decree, and/or we may be subject to future proceedings and litigation relating to the matters addressed in the amended consent decree. As of March 31, 2014, we do not believe that a loss is probable in connection with the amended consent decree, and accordingly, we have no reserves associated with compliance with the amended consent decree.
	Other Matters. In addition to the matters described above, we are and from time to time become involved in other litigation and regulatory matters incidental to our business, including, but not limited to, product liability claims, employment matters, commercial disputes, intellectual property matters, inclusion as a potentially responsible party for environmental clean-up costs, and litigation in connection with acquisitions and divestitures. We intend to defend ourselves in such matters and do not currently believe that the outcome of such matters will have a material adverse effect on our financial condition, results of operations or cash flows.
	We may also determine that products manufactured or marketed by us, or our sales and marketing practices for such products, do not meet our specifications, published standards or regulatory requirements. When a quality or regulatory issue is identified, we investigate the issue and take appropriate corrective action. We may be required to report such issues to regulatory authorities, which could result in fines, sanctions or other penalties. In some cases, we may also withdraw a product from the market, correct a product at the customer location, notify the customer of revised labeling and take other actions. We have recalled, and/or conducted field alerts relating to, certain of our products from time to time. These activities can lead to costs to repair or replace affected products, temporary interruptions in product sales and action by regulators, and can impact reported results of operations. We currently do not believe that these activities (other than those specifically disclosed herein) have had or will have a material adverse effect on our business, cash flows, financial position, or results of operations.

Financial_Instruments

Financial Instruments	9 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial Instruments	'
	FINANCIAL INSTRUMENTS
	We use derivative instruments to partially mitigate our business exposure to foreign currency exchange and interest rate risk. We may enter into foreign currency forward contracts to offset some of the foreign exchange risk of expected future cash flows on certain forecasted revenues and expenses and on certain assets and liabilities. We hedge foreign currency exposure up to a maximum period of twelve months. We may also enter into interest rate swap agreements to manage variability of expected future cash flows and interest expense related to our existing debt, and future debt issuances.
	The following table summarizes the fair value of our assets related to derivatives designated as hedging instruments including the impact of master netting arrangements and rights of offset as of March 31, 2014 and June 30, 2013:
						Gross Amounts Not
						Offset in the Consolidated
						Balance Sheet
		Gross Amounts				Financial Instruments					Net Amount
	(in millions)	March 31,		June 30,		March 31,			June 30,		March 31,		June 30,
		2014		2013		2014			2013		2014		2013
	Assets:
	Derivatives Designated as Hedging Instruments:
	Forward Interest Rate Swap Agreements1	$	31	$	34	$	(4	)	$	—	$	27	$	34
	Total Assets	$	31	$	34	$	(4	)	$	—	$	27	$	34
	Liabilities:
	Derivatives Designated as Hedging Instruments:
	Forward Interest Rate Swap Agreements2	$	5	$	—	$	(4	)	$	—	$	1	$	—
	Total Liabilities	$	5	$	—	$	(4	)	$	—	$	1	$	—
	________________
	1 All forward interest rate swap agreements classified as derivative assets are recorded as “Other Current Assets” or “Other Assets” in the unaudited condensed consolidated balance sheets, depending on the expected settlement dates.
	2 All forward interest rate swap agreements classified as derivative liabilities are recorded as “Other Current Liabilities” or “Other Liabilities” in the unaudited condensed consolidated balance sheets, depending on the expected settlement dates.
	Cash Flow Hedges. We may enter into foreign currency forward contracts to protect the value of anticipated foreign currency revenues and expenses associated with certain forecasted transactions. We also enter into interest rate swap contracts with various counterparties to hedge the variability in future interest rates due to changes in the benchmark interest rate that may impact the variability of expected future cash flows. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain (loss) on the derivative instrument is reported as a component of Accumulated Other Comprehensive Income (“AOCI”) and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. The ineffective portion of the gain (loss) on the derivative instrument is recognized in earnings immediately. The impact of interest rate swap contract and foreign currency forward contract cash flow hedges, if any, is included in the unaudited condensed consolidated statements of cash flows in “Other Accrued Liabilities and Operating Items, Net”.
	No foreign currency forward contracts were outstanding at March 31, 2014 and June 30, 2013. At March 31, 2014 and June 30, 2013, we held forward interest rate swap contracts to hedge probable, but not firmly committed, future transactions associated with our debt. The outstanding cash flow hedges are not subject to netting arrangements between the counterparties.
	The notional amount of the outstanding cash flow hedges related to interest rate swap agreements was $670 million and $450 million as of March 31, 2014 and June 30, 2013, respectively.
	During the quarter ended March 31, 2014, we entered into forward interest rate swap agreements with the aggregate notional amount totaling $220 million. These agreements hedge the variability in future interest rates due to changes in the benchmark interest rate that may impact the variability of expected future cash flows.
	During the year ended June 30, 2012, we entered into forward interest rate swap agreements with the aggregate notional amount totaling $750 million. During the year ended June 30, 2013, the forward interest swap agreement with an aggregate notional amount totaling $300 million expired. These agreements hedge the variability in future interest rates due to changes in the benchmark interest rate.
	Credit risk of these agreements was not material as of March 31, 2014 and June 30, 2013. The unrealized net gain included in AOCI on the consolidated balance sheet was $26 million and $34 million at March 31, 2014 and June 30, 2013, respectively. The amounts reclassified from AOCI to the consolidated statements of income for the quarters and nine months ended March 31, 2014 and 2013 were not material. There was no ineffectiveness associated with these derivative instruments for the quarter and nine months ended March 31, 2014.
	Fair Value (Non-Designated) Hedges. We enter into foreign currency forward contracts to manage foreign exchange exposure related to intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period. The gain (loss) recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in the unaudited condensed consolidated statements of income in “Interest Expense and Other, Net”. The maximum period of time that we hedge exposure for foreign currency fair value hedges is 31 days.
	The notional amount of the fair value hedges outstanding related to foreign currency forward contracts was $59 million and $71 million as of March 31, 2014 and June 30, 2013, respectively.
	During the quarters ended March 31, 2014 and 2013, we recognized $1 million of loss, respectively, within “Interest Expense and Other, Net”, for foreign currency forward contracts. During the nine months ended March 31, 2014 and 2013, we recognized $3 million and $1 million of loss, respectively, within “Interest Expense and Other, Net”, for foreign currency forward contracts.
	The following is a summary of all unsettled derivative instruments and the associated amount we would have paid or received to terminate these contracts based on quoted market prices for the same or similar instruments as of March 31, 2014 and June 30, 2013:
		March 31,				June 30,
		2014				2013
	(in millions)	Notional Amount		Fair Value of Unrealized Gain/(Loss)		Notional Amount			Fair Value of Unrealized Gain/(Loss)
	Foreign Currency Forward Contracts	$	59	$	—	$	71		$	—
	Interest Rate Swap Agreements	670		26		450			34
	Total	$	729	$	26	$	521		$	34

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value as of March 31, 2014 and June 30, 2013:
		As of March 31, 2014
	(in millions)	Total		Level 1		Level 2		Level 3
	Financial Assets:
	Cash Equivalents	$	952	$	952	$	—	$	—
	Other Investments	23		20		3		—
	Interest Rate Swap Agreements	31		—		31		—
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Assets	$	1,006	$	972	$	34	$	—
	Financial Liabilities:
	Contingent Consideration	$	7	$	—	$	—	$	7
	Interest Rate Swap Agreements	5		—		5		—
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Liabilities	$	12	$	—	$	5	$	7
		As of June 30, 2013
	(in millions)	Total		Level 1		Level 2		Level 3
	Financial Assets:
	Cash Equivalents	$	1,552	$	1,552	$	—	$	—
	Other Investments	19		19		—		—
	Interest Rate Swap Agreements	34		—		34		—
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Assets	$	1,605	$	1,571	$	34	$	—
	Financial Liabilities:
	Contingent Consideration	$	5	$	—	$	—	$	5
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Liabilities	$	5	$	—	$	—	$	5
	The cash equivalents balance is comprised of highly liquid investments purchased with a maturity of three months or less from the original purchase date. The other investments balance includes investments in mutual funds classified as “Other Assets” in the unaudited condensed consolidated balance sheets, all related to our deferred compensation plan. Both the cash equivalents and other investments classified as Level 1 were valued based on quoted market prices for identical instruments. Assets classified as Level 2 relate to a portion of other investments not classified as Level 1, foreign currency forward contracts, and interest rate swap agreements. Liabilities classified as Level 2 relate to foreign currency forward contracts and interest rate swap agreements. The fair value of other investments classified as Level 2 is determined based on quoted market prices for similar instruments or observable inputs other than quoted market prices. The fair value of foreign currency forward contracts is determined by using observable market spot rates and forward points adjusted by risk-adjusted discount rates. The fair value of interest rate swap agreements is determined by using methodologies similar in nature to those of our foreign currency forward contracts. The value of our derivatives represents the present value of amounts estimated to be received for the assets at the measurement date from a marketplace participant in settlement of these instruments. See note 13 to the unaudited condensed consolidated financial statements. The amount of assets classified as Level 3 at March 31, 2014 and June 30, 2013 were not material.
	Liabilities classified as Level 3 relate to business combination contingent consideration arrangements and are recorded within either “Other Accrued Liabilities” or “Other Liabilities” in the unaudited condensed consolidated balance sheets based on the timing of the associated underlying payments. The corresponding purchase agreements require future payments based on the achievement of certain post-combination performance metrics of the acquired businesses, such as net revenues, gross profit, or date of first commercial sale. The fair values of the expected future payments to be made are primarily estimated by utilizing a Monte Carlo valuation model involving the use of significant unobservable inputs. The future estimated payments are recorded at present value using discount rates adjusted for the level of risk commensurate with each acquired business, and are re-measured at each reporting period. Changes in the estimated fair values of future payments are recorded in the unaudited condensed consolidated statements of income in either “Selling, General and Administrative Expense” or “Research and Development Expense” based on the nature of each acquired business.
	The following table summarizes the changes in liabilities classified as contingent consideration:
	(in millions)	Total
	Future Gross Expected Payments at June 30, 2013	$	13
	Carrying Value at June 30, 2013	$	5
	Acquisition Date Fair Value of Contingent Consideration	2
	Change in Fair Value Included in Expense	—
	Payments	—
	Carrying Value at March 31, 2014	$	7
	Future Gross Expected Payments at March 31, 2014	$	16
	Other Instruments. The estimated fair value of our long-term obligations and other short-term borrowings was $1,557 million and $1,572 million as of March 31, 2014 and June 30, 2013, respectively, as compared to the net carrying amounts of $1,456 million and $1,446 million at March 31, 2014 and June 30, 2013, respectively. The fair value of our senior notes at March 31, 2014 and June 30, 2013 was based on quoted market prices, which involved the use of Level 1 inputs. The fair value of the other obligations at March 31, 2014 and June 30, 2013, was based on the quoted market prices for either the same or similar debt, which involved the use of observable Level 2 inputs. The fair values of the Rowa debt facility and Vital Signs indebtedness at March 31, 2014 and the Rowa debt facility at June 30, 2013 were determined using discounted cash flow analyses, which approximated carrying values. We considered the interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs. See note 10 for further information.

Product_Warranties

Product Warranties	9 Months Ended
	Mar. 31, 2014
Product Warranties Disclosures [Abstract]	'
Product Warranties	'
	PRODUCT WARRANTIES
	We offer warranties on certain products for various periods of time. We accrue for the estimated cost of product warranties at the time revenue is recognized. Our product warranty liability reflects management’s best estimate of probable liability based on current and historical product sales data and warranty costs incurred.
	The tables below summarize the changes in the carrying amount of the liability for product warranties as of March 31, 2014 and March 31, 2013:
	(in millions)
	Balance at June 30, 2013	$	18
	Warranty Accrual	9
	Warranty Claims Paid	(5		)
	Adjustments to Preexisting Accruals	(6		)
	Balance at March 31, 2014	$	16
	(in millions)
	Balance at June 30, 2012	$	31
	Warranty Accrual	7
	Warranty Claims Paid	(16		)
	Adjustments to Preexisting Accruals	(3		)
	Balance at March 31, 2013	$	19
	As of March 31, 2014 and March 31, 2013, approximately $4 million and $7 million, respectively, of the ending liability balances related to accruals for product recalls.

Segment_Information

Segment Information	9 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	SEGMENT INFORMATION
	Our operations are principally managed on a products and services basis, and the Medical Systems and Procedural Solutions segments focus primarily on our medical equipment business lines and disposable products business lines, respectively.
	We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (“CODM”), for making decisions and assessing performance as the source of our reportable segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment using information about its revenues and operating income (loss) before interest and taxes. We have determined our reportable segments as follows based on the information used by the CODM.
	Medical Systems. The Medical Systems segment is organized around our medical equipment business lines. Within the Medical Systems segment, we operate our Dispensing Technologies, Infusion Systems and Respiratory Technologies business lines. The Dispensing Technologies business line includes equipment and related services for medication and supply dispensing. The Infusion Systems business line includes infusion pumps and dedicated disposable infusion sets and accessories. The Respiratory Technologies business line includes respiratory ventilators and dedicated disposable ventilator circuits and accessories, as well as our respiratory diagnostics products. We also include our data mining surveillance service business within the Medical Systems segment, which we report as “Other.”
	Procedural Solutions. The Procedural Solutions segment is organized around our disposable products and reusable surgical instruments business lines. Within the Procedural Solutions segment, we operate our Infection Prevention, Medical Specialties and Specialty Disposables business lines. The Infection Prevention business line includes single-use skin antiseptic and other patient-preparation products and non-dedicated disposable IV infusion administration sets and accessories. The Medical Specialties business line includes interventional specialty products used for biopsy, drainage and other procedures, as well as reusable surgical instruments. The Specialty Disposables business line includes non-dedicated disposable ventilator circuits, single-use consumables for respiratory care and anesthesiology, and oxygen masks used in respiratory therapy.
	We evaluate the performance of our operating segments based upon, among other things, segment profit. Segment profit is segment revenue less segment cost of products sold, Selling, General and Administrative (“SG&A”) expenses, research and development expenses and restructuring and acquisition integration charges. With the exception of testing for goodwill impairment, we do not identify or allocate assets by operating segment; accordingly, certain segment related disclosures with respect to assets have been omitted. See note 8.
	The following table presents information about our reportable segments for the quarters ended March 31, 2014 and 2013:
	(in millions)	Medical		Procedural			Total
		Systems		Solutions
	March 31, 2014:
	External Revenues	$	571	$	397		$	968
	Depreciation and Amortization	32		21			53
	Operating Income	104		55			159
	March 31, 2013:
	External Revenues	$	584	$	317		$	901
	Depreciation and Amortization	33		13			46
	Operating Income	122		54			176
	A reconciliation of total segment operating income to consolidated income before income tax is presented below for the quarters ended March 31, 2014 and 2013:
		Quarters Ended
		March 31,
	(in millions)	2014		2013
	Total Segment Operating Income	$	159	$	176
	Reserve for Expected Government Settlement	—		(41		)
	Operating Income	159		135
	Interest Expense and Other, Net	27		17
	Income Before Income Tax	$	132	$	118
	The following table presents information about our reportable segments for the nine months ended March 31, 2014 and 2013:
	(in millions)	Medical		Procedural			Total
		Systems		Solutions
	March 31, 2014:
	External Revenues	$	1,682	$	1,038		$	2,720
	Depreciation and Amortization	96		50			146
	Operating Income	287		140			427
	March 31, 2013:
	External Revenues	$	1,737	$	910		$	2,647
	Depreciation and Amortization	98		39			137
	Operating Income	347		143			490
	A reconciliation of total segment operating income to consolidated income before income tax is presented below for the nine months ended March 31, 2014 and 2013:
		Nine Months Ended
		March 31,
	(in millions)	2014		2013
	Total Segment Operating Income	$	427	$	490
	Reserve for Expected Government Settlement	—		(41		)
	Operating Income	427		449
	Interest Expense and Other, Net	68		55
	Income Before Income Tax	$	359	$	394
	The following table presents revenue and net property and equipment by geographic area:
		Revenue									Property and Equipment, Net
		Quarters Ended					Nine Months Ended				As of		As of
		March 31,					March 31,				March 31,		June 30,
	(in millions)	2014		2013			2014		2013		2014		2013
	United States	$	742	$	709		$	2,100	$	2,081	$	327	$	304
	International	226		192			620		566		115		105
	Total	$	968	$	901		$	2,720	$	2,647	$	442	$	409
	The following table presents the revenue information for select business lines within each of our reportable segments for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended					Nine Months Ended
		March 31,					March 31,
	(in millions)	2014		2013			2014		2013
	Medical Systems
	Dispensing Technologies	$	233	$	234		$	680	$	738
	Infusion Systems	238		246			704		678
	Respiratory Technologies	94		97			278		300
	Other	6		7			20		21
Total Medical Systems	$	571	$	584		$	1,682	$	1,737
Procedural Solutions
Infection Prevention	$	168	150			$	485	$	446
Medical Specialties	91		88			269		254
Specialty Disposables	138		79			284		210
Total Procedural Solutions	$	397	$	317		$	1,038	$	910
Total CareFusion	$	968	$	901		$	2,720	$	2,647

Subsequent_Events_Notes

Subsequent Events (Notes)	9 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	SUBSEQUENT EVENTS
	In August 2013, we announced that our Board of Directors had approved a new share repurchase program authorizing the repurchase of up to $750 million of our common stock. Under this program, we are authorized to repurchase our shares in open market and private transactions through December 2015. During the quarter ended March 31, 2014, we purchased a total of 2.5 million shares under this program for an aggregate of $103 million (excluding commissions and fees). During the nine months ended March 31, 2014, we purchased a total of 10.6 million shares under this program for an aggregate of $410 million (excluding commissions and fees). From April 1, 2014 through the date of this filing, we purchased an additional 0.9 million shares under this program for an aggregate of $35 million (excluding commissions and fees).

Basis_Of_Presentation_Policies

Basis Of Presentation (Policies)	9 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis Of Presentation	'
	Basis of Presentation. Unless the context otherwise requires, references in these notes to the unaudited condensed consolidated financial statements to “CareFusion Corporation”, “CareFusion”, “we”, “us”, “our”, “the company” and “our company” refer to CareFusion Corporation and its consolidated subsidiaries. References in these notes to the unaudited condensed consolidated financial statements to “Cardinal Health” refer to Cardinal Health, Inc., an Ohio corporation, and its consolidated subsidiaries.
	We were incorporated in Delaware on January 14, 2009 for the purpose of holding the clinical and medical products businesses of Cardinal Health in anticipation of spinning off from Cardinal Health. We completed the spinoff from Cardinal Health on August 31, 2009.
	The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at June 30, 2013 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended June 30, 2013, filed with the SEC with our Annual Report on Form 10-K on August 9, 2013 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
	We have evaluated subsequent events for recognition or disclosure through the date these financial statements were issued.
	Our two global operating and reportable segments are Medical Systems and Procedural Solutions, which focus primarily on our medical equipment business lines and disposable products business lines, respectively:
New Accounting Pronouncements (Adopted During Fiscal Year 2014)	'
	New Accounting Pronouncements (Adopted during Fiscal Year 2014)
	ASU 2011-11 & ASU 2013-01. In December 2011 the Financial Accounting Standards Board (“FASB”) issued ASU 2011-11 – Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”), and in January 2013 issued ASU 2013-01 – Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (“ASU 2013-01”). ASU 2011-11 addresses disclosure differences between GAAP and International Financial Reporting Standards regarding balance sheet offsetting of certain derivative and repurchase agreement arrangements. ASU 2013-01 clarifies the scope of the provisions of ASU 2011-11. We adopted the requirements of ASU 2011-11 and ASU 2013-01 during the quarter ended September 30, 2013. The adoptions of ASU 2011-11 and ASU 2013-01 had no material impact on our financial condition, results of operations or cash flows.
	ASU 2013-02. In February 2013, the FASB issued ASU 2013-02 – Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). ASU 2013-02 requires public entities to include information about both (i) changes in Accumulated Other Comprehensive Income (“AOCI”) by component, and (ii) significant items reclassified out of AOCI. We adopted the requirements of ASU 2013-02 during the quarter ended September 30, 2013. The adoption of ASU 2013-02 had no material impact on our financial condition, results of operations or cash flows.

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Schedule of Business Acquisitions	'
	The following table summarizes the preliminary allocation of the net purchase price to the fair values of the tangible and identifiable intangible assets acquired and liabilities assumed in connection with the first and second closings, based on their estimated fair values at the applicable acquisition date. Certain estimated values, including goodwill, intangible assets and deferred income taxes, are not yet finalized pending the final settlement of the purchase price and purchase price allocations and are subject to change once additional information is obtained. Balances are reflected in the accompanying condensed consolidated balance sheets as of March 31, 2014.
	(in millions)	First			Second
		Closing			Closing
	Cash Paid	$	473		$	17
	Cash and Cash Equivalents Acquired, Less Estimated Net Working Capital Adjustments	(13		)	—
	Net Purchase Price	$	460		$	17
	(in millions)	First			Second
		Closing			Closing
	Trade Receivables	$	20		$	—
	Inventories	31			8
	Other Current Assets	13			—
	Property and Equipment	35			—
	Intangible Assets	302			—
	Goodwill	207			10
	Current Liabilities and Borrowings	(41		)	(1		)
	Deferred Income Taxes	(102		)	—
	Other Long-Term Liabilities	(5		)	—
	Net Assets Acquired	$	460		$	17

Investments_in_Unconsolidated_1

Investments in Unconsolidated Entities (Tables)	9 Months Ended
	Mar. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
Equity and Cost Method Investments	'
	The following table sets forth information relating to these investments:
	(in millions)	March 31,		June 30,
		2014		2013
	Equity Method Investments
	Cost	$	90	$	—
	Share of Net Earnings of Equity Method Investee	1		—
	Carrying Value of Equity Method Investments	$	91	$	—
	Cost Method Investments
	Carrying Value of Cost Method Investments	$	4	$	—
	Total Investments in Unconsolidated Entities	$	95	$	—

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Reconciliation Of Basic And Diluted Earnings Per Share	'
	The following table sets forth the reconciliation of basic and diluted earnings per share for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended		Nine Months Ended
		March 31,		March 31,
	(shares in millions)	2014	2013	2014	2013
	Denominator for Basic Earnings per Share	208	222.5	210.8	222.4
	Effect of Dilutive Securities:
	Stock Options	2	1.9	2.1	1.4
	Restricted Stock Units and Performance Stock Units	1.1	1.2	1.1	1.2
	Denominator for Diluted Earnings per Share - Adjusted for Dilutive Securities	211.1	225.6	214	225

Restructuring_And_Acquisition_1

Restructuring And Acquisition Integration Charges (Tables)	9 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Summary Of Restructuring And Acquisition Integration Charges	'
	The following is a summary of restructuring and acquisition integration charges for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended				Nine Months Ended
		March 31,				March 31,
	(in millions)	2014		2013		2014			2013
	Restructuring Charges	$	7	$	9	$	28		$	14
	Acquisition Integration Charges	2		—		2			—
	Total Restructuring and Acquisition Integration Charges	$	9	$	9	$	30		$	14
Schedule Of Current Restructuring Programs	'
	The following tables include information regarding our current restructuring programs:
		Nine Months Ended March 31, 2014
	(in millions)	Accrued at		Accrued Costs		Cash Payments			Accrued at March 31, 20141
		June 30, 20131
	Total Restructuring Programs	$	7	$	28	$	(22	)	$	13
	________________
	1 Included within “Other Accrued Liabilities” in the unaudited condensed consolidated balance sheets.
		Nine Months Ended March 31, 2013
	(in millions)	Accrued at		Accrued Costs2		Cash Payments			Accrued at March 31, 20131
		June 30, 20121
	Total Restructuring Programs	$	10	$	14	$	(15	)	$	9
	________________
	1 Included within “Other Accrued Liabilities” in the unaudited condensed consolidated balance sheets.
	2 Cash payments associated with accrued restructuring costs are expected to occur through the end of fiscal year 2015.
Schedule Of Segment Restructuring Charges	'
	The following table segregates our restructuring charges into our reportable segments for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended				Nine Months Ended
		March 31,				March 31,
	(in millions)	2014		2013		2014			2013
	Medical Systems	$	3	$	7	$	16		$	10
	Procedural Solutions	4		2		12			4
	Total Restructuring Charges	$	7	$	9	$	28		$	14

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule Of Inventories	'
	Inventories, accounted for at the lower of cost or market on the FIFO method, consisted of the following:
	(in millions)	March 31,			June 30,
		2014			2013
	Raw Materials	$	169		$	141
	Work-in-Process	31			23
	Finished Goods	312			264
		512			428
	Reserve for Excess and Obsolete Inventories	(52		)	(44		)
	Inventories, Net	$	460		$	384

Financing_Receivables_Tables

Financing Receivables (Tables)	9 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Schedule Of Change In Allowance For Credit Losses On Financing Receivables	'
	The change in the allowance for credit losses on financing receivables for the nine months ended March 31, 2014 consisted of the following:
	(in millions)
	Balance of allowance for credit losses at June 30, 2013	$	7
	Charge-offs	—
	Recoveries	—
	Provisions	—
	Balance of allowance for credit losses at March 31, 2014	$	7
Summary Of Credit Losses And Recorded Investment In Sales-Type Leases	'
	The following table summarizes the credit losses and recorded investment in sales-type leases as of March 31, 2014:
	(in millions)
	Allowance for credit losses:
	Balance at March 31, 2014	$	7
	Balance: individually evaluated for impairment	$	2
	Balance: collectively evaluated for impairment	$	5
	Net Investment in Sales-Type Leases:
	Balance at March 31, 2014	$	1,281
	Balance: individually evaluated for impairment	$	3
	Balance: collectively evaluated for impairment	$	1,278

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary Of Changes In Carrying Amount Of Goodwill, Net Of Adjustments For Discontinued Operations	'
	The following table summarizes the changes in the carrying amount of goodwill:
	(in millions)	Total
	Balance at June 30, 2013	$	3,081
	Goodwill Acquired, Net of Purchase Price Adjustments	223
	Foreign Currency Translation Adjustments	3
	Balance at March 31, 2014	$	3,307
Schedule Of Intangible Assets	'
	Intangible assets with definite lives are amortized over their useful lives which range from 1 to 20 years. The detail of intangible assets by class is as follows:
	(in millions)		Weighted		Gross Intangibles				Accumulated				Net Intangibles
			Average Life (years)						Amortization
	31-Mar-14
	Unamortized Intangibles:
	Trademarks		Indefinite		307				—				307
	Total Unamortized Intangibles				307				—				307
	Amortized Intangibles:
	Trademarks and Patents1		10		99				53				46
	Developed Technology2		10		450				233				217
	Customer Relationships1		18		745				295				450
	Other		7		61				38				23
	Total Amortized Intangibles		14		1,355				619				736
	Total Intangibles				$	1,662			$	619			$	1,043
	June 30, 2013
	Unamortized Intangibles:
	In-Process Research and Development2		Indefinite		$	45			$	—			$	45
	Trademarks		Indefinite		307				—				307
	Total Unamortized Intangibles				352				—				352
	Amortized Intangibles:
	Trademarks and Patents		11		88				47				41
	Developed Technology		9		368				200				168
	Customer Relationships		16		480				275				205
	Other		7		61				34				27
	Total Amortized Intangibles		12		997				556				441
	Total Intangibles				$	1,349			$	556			$	793
	________________
	1 During the quarter ended December 31, 2013, we acquired Vital Signs, which resulted in recognition of $261 million of customer relationships, $31 million of developed technology, and $10 million of trademarks and patents, which have estimated weighted average useful lives of 20 years, 7 years and 6 years, respectively.
	2 During the quarter ended March 31, 2014, we reclassified in-process research and development associated with the Medegen acquisition to developed technology due to commercialization. The developed technology will be amortized over 15 years.
Schedule Of Amortization Expense	'
	Amortization expense is as follows:
			Quarters Ended								Nine Months Ended
			March 31,								March 31,
	(in millions)		2014				2013				2014				2013
	Amortization Expense		$	25			$	19			$	62			$	56
Schedule Of Amortization Expense For Each Of Next Five Fiscal Years	'
	Amortization expense for each of the next five fiscal years is estimated to be:
	(in millions)		2014				2015				2016				2017		2018
	Amortization Expense		$	86			$	85			$	86			$	81	$	70

Reclassifications_Out_Of_Accum1

Reclassifications Out Of Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Summary of Activity of Comprehensive Income (Loss)	'
	The summary of activity of comprehensive income (loss) for the quarter and nine months ended March 31, 2014 is as follows:
		Before-Tax			Tax (Expense) or Benefit			Net-of-Tax Amount
	Quarter Ended March 31, 2014	Amount
	Foreign Currency Translation Adjustments:
	Translation Adjustments Arising During the Period	$	5		$	—		$	5
	Reclassification Adjustments Recognized in Net Income	—			—			—
	Net Foreign Currency Translation Adjustments	5			—			5
	Interest Rate Swaps:
	Unrealized Gain (Loss) Arising During the Period	(26		)	10			(16		)
	Reclassification Adjustment Recognized in Net Income	—			—			—
	Net Gain (Loss) on Interest Rate Swaps	(26		)	10			(16		)
	Total Other Comprehensive Income (Loss)	$	(21	)	$	10		$	(11	)
		Before-Tax			Tax (Expense) or Benefit			Net-of-Tax Amount
	Nine Months Ended March 31, 2014	Amount
	Foreign Currency Translation Adjustments:
	Translation Adjustments Arising During the Period	$	26		$	(2	)	$	24
	Reclassification Adjustments Recognized in Net Income	—			—			—
	Net Foreign Currency Translation Adjustments	26			(2		)	24
	Interest Rate Swaps:
	Unrealized Gains (Loss) Arising During the Period	(8		)	3			(5		)
	Reclassification Adjustment Recognized in Net Income	—			—			—
	Net Gain (Loss) on Interest Rate Swaps	(8		)	3			(5		)
	Total Other Comprehensive Income (Loss)	$	18		$	1		$	19

Borrowings_Tables

Borrowings (Tables)	9 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule Of Borrowings	'
	Borrowings consisted of the following:
	(in millions)	March 31,		June 30,
		2014		2013
	Senior Notes due 2014, 5.125% Less Unamortized Discount of $0.7 million at March 31, 2014 and $1.8 million at June 30, 2013, Effective Rate 5.49%	$	449	$	448
	Senior Notes due 2019, 6.375% Less Unamortized Discount of $9.9 million at March 31, 2014 and $11.0 million at June 30, 2013, Effective Rate 6.69%	690		689
	Senior Notes due 2023, 3.300% Less Unamortized Discount of $2.0 million at March 31, 2014 and $2.2 million at June 30, 2013, Effective Rate 3.39%	298		298
	Euro Denominated Debt, Interest Averaging 3.52% at March 31, 2014 and 3.53% at June 30, 2013, Due in Varying Installments through 2020	10		11
	Other Obligations; Interest Averaging 6.45% at March 31, 2014 and 12.43% at June 30, 2013, Due in Varying Installments through 2017	9		—
	Total Borrowings	1,456		1,446
	Less: Current Portion	457		2
	Long-Term Portion	$	999	$	1,444

Financial_Instruments_Tables

Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule Of Fair Value Of Assets And Liabilities Related To Derivative Instruments	'
	The following table summarizes the fair value of our assets related to derivatives designated as hedging instruments including the impact of master netting arrangements and rights of offset as of March 31, 2014 and June 30, 2013:
						Gross Amounts Not
						Offset in the Consolidated
						Balance Sheet
		Gross Amounts				Financial Instruments					Net Amount
	(in millions)	March 31,		June 30,		March 31,			June 30,		March 31,		June 30,
		2014		2013		2014			2013		2014		2013
	Assets:
	Derivatives Designated as Hedging Instruments:
	Forward Interest Rate Swap Agreements1	$	31	$	34	$	(4	)	$	—	$	27	$	34
	Total Assets	$	31	$	34	$	(4	)	$	—	$	27	$	34
	Liabilities:
	Derivatives Designated as Hedging Instruments:
	Forward Interest Rate Swap Agreements2	$	5	$	—	$	(4	)	$	—	$	1	$	—
	Total Liabilities	$	5	$	—	$	(4	)	$	—	$	1	$	—
	________________
	1 All forward interest rate swap agreements classified as derivative assets are recorded as “Other Current Assets” or “Other Assets” in the unaudited condensed consolidated balance sheets, depending on the expected settlement dates.
	2 All forward interest rate swap agreements classified as derivative liabilities are recorded as “Other Current Liabilities” or “Other Liabilities” in the unaudited condensed consolidated balance sheets, depending on the expected settlement dates.
Schedule Of Unsettled Derivative Instruments And Associated Amount	'
	The following is a summary of all unsettled derivative instruments and the associated amount we would have paid or received to terminate these contracts based on quoted market prices for the same or similar instruments as of March 31, 2014 and June 30, 2013:
		March 31,				June 30,
		2014				2013
	(in millions)	Notional Amount		Fair Value of Unrealized Gain/(Loss)		Notional Amount			Fair Value of Unrealized Gain/(Loss)
	Foreign Currency Forward Contracts	$	59	$	—	$	71		$	—
	Interest Rate Swap Agreements	670		26		450			34
	Total	$	729	$	26	$	521		$	34

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule Of Financial Assets And Liabilities That Are Measured At Fair Value On Recurring Basis	'
	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value as of March 31, 2014 and June 30, 2013:
		As of March 31, 2014
	(in millions)	Total		Level 1		Level 2		Level 3
	Financial Assets:
	Cash Equivalents	$	952	$	952	$	—	$	—
	Other Investments	23		20		3		—
	Interest Rate Swap Agreements	31		—		31		—
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Assets	$	1,006	$	972	$	34	$	—
	Financial Liabilities:
	Contingent Consideration	$	7	$	—	$	—	$	7
	Interest Rate Swap Agreements	5		—		5		—
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Liabilities	$	12	$	—	$	5	$	7
		As of June 30, 2013
	(in millions)	Total		Level 1		Level 2		Level 3
	Financial Assets:
	Cash Equivalents	$	1,552	$	1,552	$	—	$	—
	Other Investments	19		19		—		—
	Interest Rate Swap Agreements	34		—		34		—
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Assets	$	1,605	$	1,571	$	34	$	—
	Financial Liabilities:
	Contingent Consideration	$	5	$	—	$	—	$	5
	Foreign Currency Forward Contracts	—		—		—		—
	Total Financial Liabilities	$	5	$	—	$	—	$	5
Schedule of Changes in Contingent Consideration Liability	'
	The following table summarizes the changes in liabilities classified as contingent consideration:
	(in millions)	Total
	Future Gross Expected Payments at June 30, 2013	$	13
	Carrying Value at June 30, 2013	$	5
	Acquisition Date Fair Value of Contingent Consideration	2
	Change in Fair Value Included in Expense	—
	Payments	—
	Carrying Value at March 31, 2014	$	7
	Future Gross Expected Payments at March 31, 2014	$	16

Product_Warranties_Tables

Product Warranties (Tables)	9 Months Ended
	Mar. 31, 2014
Product Warranties Disclosures [Abstract]	'
Summary Of Changes In Carrying Amount Of Liability For Product Warranties	'
	The tables below summarize the changes in the carrying amount of the liability for product warranties as of March 31, 2014 and March 31, 2013:
	(in millions)
	Balance at June 30, 2013	$	18
	Warranty Accrual	9
	Warranty Claims Paid	(5		)
	Adjustments to Preexisting Accruals	(6		)
	Balance at March 31, 2014	$	16
	(in millions)
	Balance at June 30, 2012	$	31
	Warranty Accrual	7
	Warranty Claims Paid	(16		)
	Adjustments to Preexisting Accruals	(3		)
	Balance at March 31, 2013	$	19

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule Of Information About Reporting Segments	'
	The following table presents information about our reportable segments for the nine months ended March 31, 2014 and 2013:
	(in millions)	Medical		Procedural			Total
		Systems		Solutions
	March 31, 2014:
	External Revenues	$	1,682	$	1,038		$	2,720
	Depreciation and Amortization	96		50			146
	Operating Income	287		140			427
	March 31, 2013:
	External Revenues	$	1,737	$	910		$	2,647
	Depreciation and Amortization	98		39			137
	Operating Income	347		143			490
	The following table presents information about our reportable segments for the quarters ended March 31, 2014 and 2013:
	(in millions)	Medical		Procedural			Total
		Systems		Solutions
	March 31, 2014:
	External Revenues	$	571	$	397		$	968
	Depreciation and Amortization	32		21			53
	Operating Income	104		55			159
	March 31, 2013:
	External Revenues	$	584	$	317		$	901
	Depreciation and Amortization	33		13			46
	Operating Income	122		54			176
Reconciliation of Segment Operating Income to Consolidated	'
	A reconciliation of total segment operating income to consolidated income before income tax is presented below for the nine months ended March 31, 2014 and 2013:
		Nine Months Ended
		March 31,
	(in millions)	2014		2013
	Total Segment Operating Income	$	427	$	490
	Reserve for Expected Government Settlement	—		(41		)
	Operating Income	427		449
	Interest Expense and Other, Net	68		55
	Income Before Income Tax	$	359	$	394
	A reconciliation of total segment operating income to consolidated income before income tax is presented below for the quarters ended March 31, 2014 and 2013:
		Quarters Ended
		March 31,
	(in millions)	2014		2013
	Total Segment Operating Income	$	159	$	176
	Reserve for Expected Government Settlement	—		(41		)
	Operating Income	159		135
	Interest Expense and Other, Net	27		17
	Income Before Income Tax	$	132	$	118
Schedule Of Revenue And Net Property And Equipment By Geographic Area	'
	The following table presents revenue and net property and equipment by geographic area:
		Revenue									Property and Equipment, Net
		Quarters Ended					Nine Months Ended				As of		As of
		March 31,					March 31,				March 31,		June 30,
	(in millions)	2014		2013			2014		2013		2014		2013
	United States	$	742	$	709		$	2,100	$	2,081	$	327	$	304
	International	226		192			620		566		115		105
	Total	$	968	$	901		$	2,720	$	2,647	$	442	$	409
Schedule Of Revenue Information For Select Business Lines Within Each Of Segments	'
	The following table presents the revenue information for select business lines within each of our reportable segments for the quarters and nine months ended March 31, 2014 and 2013:
		Quarters Ended					Nine Months Ended
		March 31,					March 31,
	(in millions)	2014		2013			2014		2013
	Medical Systems
	Dispensing Technologies	$	233	$	234		$	680	$	738
	Infusion Systems	238		246			704		678
	Respiratory Technologies	94		97			278		300
	Other	6		7			20		21
	Total Medical Systems	$	571	$	584		$	1,682	$	1,737
	Procedural Solutions
	Infection Prevention	$	168	150			$	485	$	446
	Medical Specialties	91		88			269		254
	Specialty Disposables	138		79			284		210
	Total Procedural Solutions	$	397	$	317		$	1,038	$	910
	Total CareFusion	$	968	$	901		$	2,720	$	2,647

Acquisitions_Details

Acquisitions (Details) (USD $)	9 Months Ended			0 Months Ended				1 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Nov. 18, 2013	Mar. 31, 2014	Mar. 31, 2014
				Minimum [Member]	Maximum [Member]	Vital Signs [Member]	Vital Signs [Member]	Vital Signs [Member]	Vital Signs [Member]
									Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business acquisition	'	'	'	'	'	'	$500	'	'
Cash Paid	'	'	'	'	'	473	'	17	'
Cash and Cash Equivalents Acquired, Less Estimated Net Working Capital Adjustments	'	'	'	'	'	-13	'	0	'
Net Purchase Price	517	66	'	'	'	460	'	17	'
Trade Receivables	'	'	'	'	'	20	'	0	'
Inventories	'	'	'	'	'	31	'	8	'
Other Current Assets	'	'	'	'	'	13	'	0	'
Property and Equipment	'	'	'	'	'	35	'	0	'
Intangible Assets	'	'	'	'	'	302	'	0	'
Goodwill	3,307	'	3,081	'	'	207	'	10	'
Current Liabilities and Borrowings	'	'	'	'	'	-41	'	-1	'
Deferred Income Taxes	'	'	'	'	'	-102	'	0	'
Other Long-Term Liabilities	'	'	'	'	'	-5	'	0	'
Net Assets Acquired	'	'	'	'	'	460	'	17	'
Fair Value Inputs, Discount Rate	'	'	'	10.50%	12.50%	'	'	'	'
Acquisition related costs	'	'	'	'	'	'	'	'	$4

Acquisitions_Intangible_Assets

Acquisitions (Intangible Assets) (Details) (USD $)

3 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Customer Relationships [Member]

Customer Relationships [Member]

Developed Technology [Member]

Developed Technology [Member]

Trademarks And Patents [Member]

Trademarks And Patents [Member]

Vital Signs [Member]

Vital Signs [Member]

Vital Signs [Member]

Vital Signs [Member]

Customer Relationships [Member]

Developed Technology [Member]

Trademarks And Patents [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived assets acquired

'

$441

$736

$450

$205

$217

$168

$46

$41

'

$261

$31

$10

Useful lives of intangible assets

'14 years

'12 years

'

'18 years

'16 years

'10 years

'9 years

'10 years

'11 years

'18 years

'20 years

'7 years

'6 years

Investments_in_Unconsolidated_2

Investments in Unconsolidated Entities (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013
Investment [Line Items]	'	'	'	'	'	'
Cost	$90	$90	'	$90	'	$0
Share of Net Earnings of Equity Method Investee	'	1	0	1	0	'
Carrying Value of Equity Method Investments	91	91	'	91	'	0
Carrying Value of Cost Method Investments	4	4	'	4	'	0
Total Investments in Unconsolidated Entities	95	95	'	95	'	0
Equity Method Investment Call Option - Percentage Ownership Increase	40.00%	'	'	'	'	'
Investment Owned, Open Put or Call Option Flag	60.00%	'	'	'	'	'
Caesarea Medical Electronics [Member]	'	'	'	'	'	'
Investment [Line Items]	'	'	'	'	'	'
Cost	$89	$89	'	$89	'	'
Equity method investment, percentage	40.00%	40.00%	'	40.00%	'	'

Earnings_Per_Share_Reconciliat

Earnings Per Share (Reconciliation Of Basic And Diluted Earnings Per Share) (Detail)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Denominator for Basic Earnings per Share (shares)	208	222.5	210.8	222.4
Effect of Dilutive Securities:	'	'	'	'
Number of Securities (in shares)	1.7	4	1.7	6.5
Denominator for Diluted Earnings per Share - Adjusted for Dilutive Securities (shares)	211.1	225.6	214	225
Stock Options [Member]	'	'	'	'
Effect of Dilutive Securities:	'	'	'	'
Number of Securities (in shares)	2	1.9	2.1	1.4
Restricted Stock Units and Performance Stock Units [Member]	'	'	'	'
Effect of Dilutive Securities:	'	'	'	'
Number of Securities (in shares)	1.1	1.2	1.1	1.2

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Detail) (USD $)	1 Months Ended		3 Months Ended		9 Months Ended		17 Months Ended	1 Months Ended
Share data in Millions, unless otherwise specified	Aug. 31, 2013	Feb. 28, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013	6-May-14
								Subsequent Event [Member]
Earnings Per Share [Abstract]	'	'	'	'	'	'	'	'
Number of Securities (in shares)	'	'	1.7	4	1.7	6.5	'	'
Share repurchase program, authorized repurchase value	$750,000,000	$500,000,000	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Stock Repurchased During Period, Shares	'	'	2.5	'	10.6	'	15.3	0.9
Stock Repurchased During Period, Value	'	'	103,000,000	'	410,000,000	'	500,000,000	35,000,000
Share repurchase program, remaining repurchase value	'	'	'	'	$500,000,000	'	'	'

Restructuring_And_Acquisition_2

Restructuring And Acquisition Integration Charges (Summary Of Restructuring And Acquisition Integration Charges) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Restructuring and Related Activities [Abstract]	'	'	'	'
Restructuring Charges	$7	$9	$28	$14
Acquisition Integration Charges	2	0	2	0
Total Restructuring and Acquisition Integration Charges	$9	$9	$30	$14

Restructuring_And_Acquisition_3

Restructuring And Acquisition Integration Charges (Schedule Of Current Restructuring Programs) (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Restructuring Reserve [Roll Forward]	'	'
Accrued, Beginning Balance	$7	$10
Accrued Costs	28	14
Cash Payments	-22	-15
Accrued, Ending Balance	$13	$9

Restructuring_And_Acquisition_4

Restructuring And Acquisition Integration Charges (Schedule Of Segment Restructuring Charges) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total Restructuring Charges	$7	$9	$28	$14
Medical Systems [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total Restructuring Charges	3	7	16	10
Procedural Solutions [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Total Restructuring Charges	$4	$2	$12	$4

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Detail) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw Materials	$169	$141
Work-in-Process	31	23
Finished Goods	312	264
Inventory, Gross	512	428
Reserve for Excess and Obsolete Inventories	-52	-44
Inventories, Net	$460	$384

Financing_Receivables_Narrativ

Financing Receivables (Narrative) (Detail)	9 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Financing receivables past due threshold after billing date	'30 days

Financing_Receivables_Schedule

Financing Receivables (Schedule Of Change In Allowance For Credit Losses On Financing Receivables) (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Financing Receivable, Allowance for Credit Losses [Roll Forward]	'
Beginning balance of allowance for credit losses	$7
Charge-offs	0
Recoveries	0
Provisions	0
Ending balance of allowance for credit losses	$7

Financing_Receivables_Summary_

Financing Receivables (Summary Of Credit Losses And Recorded Investment In Sales-Type Leases) (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Jun. 30, 2013
Allowance for credit losses:	'	'
Balance: Allowance for credit losses	$7	$7
Balance: individually evaluated for impairment	2	'
Balance: collectively evaluated for impairment	5	'
Net Investment in Sales-Type Leases:	'	'
Balance: Sales-Type Leases	1,281	'
Balance: individually evaluated for impairment	3	'
Balance: collectively evaluated for impairment	$1,278	'

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets (Summary Of Changes In Carrying Amount Of Goodwill, Net Of Adjustments For Discontinued Operations) (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Goodwill [Roll Forward]	'
Beginning Balance	$3,081
Goodwill Acquired, Net of Purchase Price Adjustments	223
Foreign Currency Translation Adjustments	3
Ending Balance	$3,307

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets (Narrative) (Detail) (USD $)

3 Months Ended

12 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Minimum [Member]

Maximum [Member]

Medical Systems [Member]

Medical Systems [Member]

Procedural Solutions [Member]

Procedural Solutions [Member]

Vital Signs [Member]

Vital Signs [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

Trademarks And Patents [Member]

Trademarks And Patents [Member]

Trademarks And Patents [Member]

Trademarks And Patents [Member]

Vital Signs [Member]

Vital Signs [Member]

Vital Signs [Member]

Vital Signs [Member]

Medegen [Member]

Vital Signs [Member]

Vital Signs [Member]

Goodwill [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

'

$3,081

$3,307

'

'

$2,106

$2,103

$1,201

$978

$207

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful lives of intangible assets

'14 years

'12 years

'

'1 year

'20 years

'

'

'

'

'18 years

'

'18 years

'16 years

'20 years

'

'10 years

'9 years

'7 years

'

'

'10 years

'11 years

'6 years

'

Finite-lived Intangible Assets Acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$261

'

'

'

$31

'

'

'

'

$10

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 years

'

'

'

'7 years

'15 years

'

'

'

'6 years

Goodwill_And_Other_Intangible_4

Goodwill And Other Intangible Assets (Schedule Of Intangible Assets) (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Jun. 30, 2013

Mar. 31, 2014

Dec. 31, 2013

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2013

Vital Signs [Member]

In-Process Research And Development [Member]

Trademarks [Member]

Trademarks [Member]

Trademarks And Patents [Member]

Trademarks And Patents [Member]

Trademarks And Patents [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Other [Member]

Other [Member]

Vital Signs [Member]

Vital Signs [Member]

Vital Signs [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized Intangibles, Gross Intangibles

'

$352

$307

'

$45

$307

$307

'

'

'

'

'

'

'

'

'

'

'

Unamortized Intangibles, Net Intangibles

'

352

307

'

45

307

307

'

'

'

'

'

'

'

'

'

'

'

Amortized Intangibles, Weighted Average Life (years)

'14 years

'12 years

'

'18 years

'

'

'

'10 years

'11 years

'6 years

'10 years

'9 years

'7 years

'18 years

'16 years

'20 years

'7 years

'7 years

Amortized Intangibles, Gross Intangibles

'

997

1,355

'

'

'

'

99

88

'

450

368

'

745

480

'

61

61

Amortized Intangibles, Accumulated Amortization

'

556

619

'

'

'

'

53

47

'

233

200

'

295

275

'

38

34

Amortized Intangibles, Net Intangibles

'

441

736

'

'

'

'

46

41

10

217

168

31

450

205

261

23

27

Gross Intangibles

'

1,349

1,662

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated Amortization

'

556

619

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Intangibles

'

$793

$1,043

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill_And_Other_Intangible_5

Goodwill And Other Intangible Assets (Schedule Of Amortization Expense) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization Expense	$25	$19	$62	$56

Goodwill_And_Other_Intangible_6

Goodwill And Other Intangible Assets (Schedule Of Amortization Expense For Each Of Next Five Fiscal Years) (Detail) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
Amortization Expense, 2014	$86
Amortization Expense, 2015	85
Amortization Expense, 2016	86
Amortization Expense, 2017	81
Amortization Expense, 2018	$70

Reclassifications_Out_Of_Accum2

Reclassifications Out Of Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other comprehensive income (loss), before tax	($21)	'	$18	'
Other comprehensive income (loss), tax	10	'	1	'
Other Comprehensive Income, Net of Tax	-11	-2	19	28
Foreign Currency Translation Adjustments [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Adjustments during the period, before tax	5	'	26	'
Adjustments during the period, tax	0	'	-2	'
Adjustments during the period, after tax	5	'	24	'
Reclassification adjustments, before tax	0	'	0	'
Reclassification adjustments, tax	0	'	0	'
Reclassification adjustments, after tax	0	'	0	'
Other comprehensive income (loss), before tax	5	'	26	'
Other comprehensive income (loss), tax	0	'	-2	'
Other Comprehensive Income, Net of Tax	5	'	24	'
Interest Rate Swaps [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Adjustments during the period, before tax	-26	'	-8	'
Adjustments during the period, tax	10	'	3	'
Adjustments during the period, after tax	-16	'	-5	'
Reclassification adjustments, before tax	0	'	0	'
Reclassification adjustments, tax	0	'	0	'
Reclassification adjustments, after tax	0	'	0	'
Other comprehensive income (loss), before tax	-26	'	-8	'
Other comprehensive income (loss), tax	10	'	3	'
Other Comprehensive Income, Net of Tax	($16)	'	($5)	'

Borrowings_Schedule_Of_Borrowi

Borrowings (Schedule Of Borrowings) (Detail) (USD $)

Mar. 31, 2014

Feb. 03, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

In Millions, unless otherwise specified

5.125% Senior Notes, Due 2014 [Member]

5.125% Senior Notes, Due 2014 [Member]

6.375% Senior Notes, Due 2019 [Member]

6.375% Senior Notes, Due 2019 [Member]

3.300% Senior Notes, Due 2023 [Member]

3.300% Senior Notes, Due 2023 [Member]

Euro Denominated Debt, Due In Varying Installments Through 2020 [Member]

Euro Denominated Debt, Due In Varying Installments Through 2020 [Member]

Other Obligations; Due In Varying Installments Through 2017 and 2014 [Member]

Other Obligations; Due In Varying Installments Through 2017 and 2014 [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Average interest rate

'

'

'

'

'

'

'

'

'

3.52%

3.53%

6.45%

12.43%

'

'

Senior Notes, Maturity Year

'

'

'

'2014

'2014

'2019

'2019

'2023

'2023

'2020

'2020

'2017

'2017

'

'

Fixed Interest Rate

'

'

'

5.13%

5.13%

6.38%

6.38%

3.30%

3.30%

'

'

'

'

'

'

Unamortized Discount on Senior Notes

'

'

'

$0.70

$1.80

$9.80

$11

$2

$2.20

'

'

$1

'

'

'

Effective Rate

'

'

'

5.49%

5.49%

6.69%

6.69%

3.39%

3.39%

'

'

'

'

'

'

Senior Notes

'

'

'

449

448

690

689

298

298

'

'

'

'

'

'

Denominated Debt

'

50

'

'

'

'

'

'

'

10

11

'

'

0

0

Other Obligations

'

'

'

'

'

'

'

'

'

'

'

9

0

'

'

Total Borrowings

1,456

'

1,446

'

'

'

'

'

'

'

'

'

'

'

'

Less: Current Portion

457

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Long-Term Portion

$999

'

$1,444

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings_Narrative_Detail

Borrowings (Narrative) (Detail)

1 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

Mar. 31, 2013

Jul. 31, 2009

Mar. 31, 2014

Feb. 13, 2014

Feb. 03, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Dec. 10, 2012

Jul. 31, 2011

Aug. 01, 2011

Aug. 01, 2011

Aug. 31, 2012

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Feb. 13, 2014

Aug. 01, 2011

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Minimum [Member]

Maximum [Member]

4.125% Senior Notes, Due 2012 [Member]

Euro Denominated Debt, Due In Varying Installments Through 2020 [Member]

Euro Denominated Debt, Due In Varying Installments Through 2020 [Member]

Other Obligations In Chinese Yuan Due In Varying Installments Through Two Thousand Fourteen [Member]

Other Obligations In Chinese Yuan Due In Varying Installments Through Two Thousand Fourteen [Member]

Other Obligations; Due In Varying Installments Through 2017 and 2014 [Member]

Other Obligations; Due In Varying Installments Through 2017 and 2014 [Member]

Revolving Credit Facility [Member]

Euro Debt Facility [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Euro Debt Facility [Member]

Euro Debt Facility [Member]

USD ($)

USD ($)

USD ($)

USD ($)

CNY

USD ($)

USD ($)

USD ($)

EUR (€)

Unsecured Senior Notes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of aggregate principal amount of senior unsecured notes

$300,000,000

$1,400,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from sale of aggregate principal amount of senior unsecured notes

298,000,000

1,374,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Senior Debt

'

'

'

'

'

'

'

'

'

'

'

'

250,000,000

'

'

'

'

'

'

'

'

Maturities of senior debt

'

'

'

'

'

'

'

'

'

'

'

'

250,000,000

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

2.65%

3.75%

4.13%

'

'

5.60%

5.60%

'

'

'

'

Short-term Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

Assumed debt facility in connection with acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,000,000

Credit facility, amount outstanding

'

'

'

'

50,000,000

'

0

0

'

'

'

'

'

10,000,000

11,000,000

'

'

'

'

'

'

Line of Credit Facility, Increase (Decrease), Net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000,000

'

Senior unsecured revolving credit facility, principal amount

'

'

'

25,000,000

'

'

'

'

550,000,000

550,000,000

'

'

'

'

'

'

'

'

'

'

'

Increased aggregate commitments under credit facility

'

'

'

'

'

'

'

'

750,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility leverage ratio

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility interest coverage ratio

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other Obligations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,000,000

9,000,000

0

'

'

Unamortized discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Letters of credit and bank guarantees outstanding

'

'

$27,000,000

'

'

$24,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Tax_Detail

Income Tax (Detail) (USD $)	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013	Sep. 30, 2008
Income Tax Disclosure [Abstract]	'	'	'	'	'	'	'	'
Effective tax rate	23.00%	'	'	28.60%	22.90%	29.20%	'	'
U.S. federal statutory rate	35.00%	'	'	'	'	'	'	'
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$10,000,000	'	'	'	$10,000,000	'	'	'
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves	10,000,000	'	'	'	10,000,000	'	'	'
Deferred Tax Assets, Net of Valuation Allowance	0	'	'	'	0	'	'	'
Amount of additional tax proposed by the IRS	'	'	'	'	'	'	'	462,000,000
Agreement resolve amount	'	'	450,000,000	'	'	'	'	'
Tax settlement amount	'	12,000,000	'	'	'	'	80,000,000	'
Tax settlement amount, net of tax	'	11,000,000	'	'	'	'	69,000,000	'
Tax settlement amount, interest	'	$5,000,000	'	'	'	'	$26,000,000	'

Commitments_And_Contingencies_

Commitments And Contingencies (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Reserve for Expected Government Settlement	$41,000,000	$0	$41,000,000	$0	$41,000,000
Potential damages payment per day per violation	'	15,000	'	15,000	'
Potential damages payment per year	'	$15,000,000	'	'	'

Financial_Instruments_Narrativ

Financial Instruments (Narrative) (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013	Jun. 30, 2012
Derivative [Line Items]	'	'	'	'	'	'
Notional Amount Of Interest Rate Cash Flow Hedge Derivative	$220	'	$220	'	$300	$750
Fair Value Gain/(Loss)	'	'	26	'	34	'
Maximum period of time on hedge exposure for foreign currency fair value hedges	'	'	'31 days	'	'	'
Derivative, notional amount	59	'	59	'	71	'
Gain (loss) recognized on foreign currency forward contracts	1	1	3	1	'	'
Foreign Currency Forward Contracts [Member]	'	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'	'
Maximum period to hedge foreign currency exposure	'12 months	'	'	'	'	'
Forward Interest Rate Swap Agreements [Member]	'	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'	'
Notional Amount Of Interest Rate Cash Flow Hedge Derivative	$670	'	$670	'	$450	'

Financial_Instruments_Schedule

Financial Instruments (Schedule Of Fair Value Of Assets And Liabilities Related To Derivative Instruments) (Detail) (Designated as Hedging Instrument [Member], USD $)	Mar. 31, 2014	Jun. 30, 2013
In Millions, unless otherwise specified
Derivative [Line Items]	'	'
Derivative Asset, Gross Amounts	$31	$34
Derivative Asset, Gross Amount Not Offset in the Consolidated Balance Sheet	-4	0
Derivative Asset, Net Amount	27	34
Derivative Liability, Gross Amount	5	0
Derivative Liability, Gross Amount Not Offset in the Consolidated Balance Sheet	-4	0
Derivative Liability, Net Amount	1	0
Forward Interest Rate Swap Agreements [Member]	'	'
Derivative [Line Items]	'	'
Derivative Asset, Gross Amounts	31	34
Derivative Asset, Gross Amount Not Offset in the Consolidated Balance Sheet	-4	0
Derivative Asset, Net Amount	27	34
Derivative Liability, Gross Amount	5	0
Derivative Liability, Gross Amount Not Offset in the Consolidated Balance Sheet	-4	0
Derivative Liability, Net Amount	$1	$0

Financial_Instruments_Schedule1

Financial Instruments (Schedule Of Unsettled Derivative Instruments And Associated Amount) (Detail) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Jun. 30, 2013
Derivative [Line Items]	'	'
Notional Amount	$729	$521
Fair Value Gain/(Loss)	-26	-34
Foreign Currency Forward Contracts [Member]	'	'
Derivative [Line Items]	'	'
Notional Amount	59	71
Foreign Currency Forward Contracts, Fair Value Gain/(Loss)	0	0
Forward Interest Rate Swap Agreements [Member]	'	'
Derivative [Line Items]	'	'
Notional Amount	670	450
Interest Rate Swap Agreements, Fair Value Gain/(Loss)	$26	$34

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Financial Assets And Liabilities That Are Measured At Fair Value On Recurring Basis) (Detail) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Liabilities - Contingent Consideration	$7	$5
Estimate of Fair Value Measurement [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents	952	1,552
Other Investments	23	19
Assets - Interest Rate Swap Agreements	31	34
Assets - Foreign Currency Forward Contracts	0	0
Total Assets	1,006	1,605
Liabilities - Contingent Consideration	7	5
Liabilities - Interest Rate Swap Agreements	5	'
Liabilities - Foreign Currency Forward Contracts	0	0
Total Financial Liabilities	12	5
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents	952	1,552
Other Investments	20	19
Assets - Interest Rate Swap Agreements	0	0
Assets - Foreign Currency Forward Contracts	0	0
Total Assets	972	1,571
Liabilities - Contingent Consideration	0	0
Liabilities - Interest Rate Swap Agreements	0	'
Liabilities - Foreign Currency Forward Contracts	0	0
Total Financial Liabilities	0	0
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents	0	0
Other Investments	3	0
Assets - Interest Rate Swap Agreements	31	34
Assets - Foreign Currency Forward Contracts	0	0
Total Assets	34	34
Liabilities - Contingent Consideration	0	0
Liabilities - Interest Rate Swap Agreements	5	'
Liabilities - Foreign Currency Forward Contracts	0	0
Total Financial Liabilities	5	0
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash Equivalents	0	0
Other Investments	0	0
Assets - Interest Rate Swap Agreements	0	0
Assets - Foreign Currency Forward Contracts	0	0
Total Assets	0	0
Liabilities - Contingent Consideration	7	5
Liabilities - Interest Rate Swap Agreements	0	'
Liabilities - Foreign Currency Forward Contracts	0	0
Total Financial Liabilities	$7	$5

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Detail) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]	'	'
Estimated fair value of long-term obligations and other short-term borrowings	$1,557	$1,572
Net carrying amounts of long-term obligations and other short-term borrowings	$1,456	$1,446

Fair_Value_Measurements_Schedu1

Fair Value Measurements (Schedule of Changes in Contingent Consideration Liability) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Business Combination, Contingent Consideration Liability Reconciliation [Roll Forward]	'
Future Gross Expected Payments	$13
Carrying Value, beginning of period	5
Acquisition Date Fair Value of Contingent Consideration	2
Carrying Value, end of period	7
Future Gross Expected Payments	16
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	0
Proceeds from (Payments for) Other Financing Activities	$0

Product_Warranties_Summary_Of_

Product Warranties (Summary Of Changes In Carrying Amount Of Liability For Product Warranties) (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'
Beginning Balance	$18	$31
Warranty Accrual	9	7
Warranty Claims Paid	-5	-16
Adjustments to Preexisting Accruals	-6	-3
Ending Balance	$16	$19

Product_Warranties_Narrative_D

Product Warranties (Narrative) (Detail) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Millions, unless otherwise specified
Product Warranties Disclosures [Abstract]	'	'
Liability related to accruals for product recalls	$4	$7

Segment_Information_Schedule_O

Segment Information (Schedule Of Information About Reporting Segments) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'
External Revenues	$968	$901	$2,720	$2,647
Operating Income	159	135	427	449
Medical Systems [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
External Revenues	571	584	1,682	1,737
Depreciation and Amortization	32	33	96	98
Operating Income	104	122	287	347
Procedural Solutions [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
External Revenues	397	317	1,038	910
Depreciation and Amortization	21	13	50	39
Operating Income	55	54	140	143
Operating Segments [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
External Revenues	968	901	2,720	2,647
Depreciation and Amortization	53	46	146	137
Operating Income	$159	$176	$427	$490

Segment_Information_Reconcilia

Segment Information (Reconciliation of Segment Income to Consolidated) (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'	'
Operating Income	'	$159	$135	$427	$449
Reserve for Expected Government Settlement	-41	0	-41	0	-41
Interest Expense and Other, Net	'	27	17	68	55
Income Before Income Tax	'	132	118	359	394
Operating Segments [Member]	'	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'	'
Operating Income	'	$159	$176	$427	$490

Segment_Information_Schedule_O1

Segment Information (Schedule Of Revenue And Net Property And Equipment By Geographic Area) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	$968	$901	$2,720	$2,647	'
Property and Equipment, Net	442	'	442	'	409
United States [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	742	709	2,100	2,081	'
Property and Equipment, Net	327	'	327	'	304
International [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	226	192	620	566	'
Property and Equipment, Net	$115	'	$115	'	$105

Segment_Information_Schedule_O2

Segment Information (Schedule Of Revenue Information For Select Business Lines Within Each Of Segments) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	$968	$901	$2,720	$2,647
Medical Systems [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	571	584	1,682	1,737
Medical Systems [Member] | Dispensing Technologies [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	233	234	680	738
Medical Systems [Member] | Infusion Systems [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	238	246	704	678
Medical Systems [Member] | Respiratory Technologies [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	94	97	278	300
Medical Systems [Member] | Other [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	6	7	20	21
Procedural Solutions [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	397	317	1,038	910
Procedural Solutions [Member] | Infection Prevention [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	168	150	485	446
Procedural Solutions [Member] | Medical Specialties [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	91	88	269	254
Procedural Solutions [Member] | Specialty Disposables [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Revenue	$138	$79	$284	$210

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended		3 Months Ended	9 Months Ended	17 Months Ended	1 Months Ended
Share data in Millions, unless otherwise specified	Aug. 31, 2013	Feb. 28, 2012	Mar. 31, 2014	Mar. 31, 2014	Jun. 30, 2013	6-May-14
						Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'
Share repurchase program, authorized repurchase value	$750,000,000	$500,000,000	'	'	'	'
Stock Repurchased During Period, Shares	'	'	2.5	10.6	15.3	0.9
Stock Repurchased During Period, Value	'	'	$103,000,000	$410,000,000	$500,000,000	$35,000,000